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Summary 
	
Interpretation	 of	 laboratory	 tests	 in	 clinical	 practice	 is	 based	 on	 an	 understanding	 of	 the	
disease	 process	 within	 or	 between	 individuals.	 This	 is	 demonstrated	 by	 the	 variability	 of	
pathology	results	as	compared	to	the	previous	result	or	against	the	reference	range,	made	up	
from	 the	 intrinsic	 pathophysiological	 changes	 and	 also	 variation	 associated	with	 the	 in	 vitro	
changes	to	the	sample.	My	work	is	on	identification	and	minimisation	of	the	result	variation	in	
the	 pre-analytical	 phase,	 accounting	 for	 60-70%	 of	 the	 errors	 associated	 with	 laboratory	
testing.	
	
The	 first	 project	 of	my	 thesis	 is	 based	 on	 four	 studies	 that	 consider	 the	 in	 vitro	 stability	 of	
parathyroid	 hormone	 (PTH)	 and	 C-reactive	 protein	 (CRP),	 in	 which	 significant	 sample	
degradation	is	observed	due	to	sample	tube	type,	anticoagulant	used	and	time	to	separation.		
	
The	 second	 project	 considers	 ethnic	 variation	 as	 a	 source	 of	 intra	 individual	 variation.	
Specifically	 considering	 intra	 individual	 ethnic	 variation	 in	 total	 cholesterol	 (TC)	 and	 high	
density	 lipoprotein	 cholesterol	 (HDLC),	 reporting	 significant	 differences	 were	 observed	
between	 Caucasian	 Indo-Asians	 in	HDLC,	 in	 addition	 I	 investigated	 the	 relationship	 between	
low	maternal	vitamin	B12	concentrations	in	Caucasian	women	and	cord	blood	cholesterol.	
	
The	third	project	considered	the	variation	in	 laboratory	results	due	to	pre-existing	conditions	
causing	 interference	 in	 common	 laboratory	 tests.	 I	 published	 on	 the	 effect	 of	 lipaemia	 on	
common	laboratory	tests,	showing	lipaemia	does	have	a	significant	effect	on	laboratory	tests.	
The	 following	 study	 found	 that	 the	 raised	 prolactin	 seen	 in	 rheumatoid	 arthritis	 is	 not	
artefactual	but	due	to	changes	in	cross	reactivity	due	of	prolactin	subtypes.	The	final	paper	of	
this	project	shows,	through	a	collection	of	case	studies	falsely	elevated	serum	calcium	levels	in	
patients	with	paraproteinaemia.	
		
I	 conclude	 with	 two	 studies	 that	 demonstrate	 how	 inappropriate	 test	 selection	 can	 cause	
variability	and	therefore	affect	the	utility	of	a	test.	My	papers	in	this	area	have	been	cited	over	
140	times.	
	
Word	count	306	 	
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Chapter	1 Background	
	
The	diagnosis	and	management	of	patients	increasingly	relies	on	the	use	of	laboratory	testing	
with	Pathology	requests	in	100%	of	care	records,	80%	patient	episodes	(1).	However,	the	true	
value	of	pathology	testing,	to	the	requestor,	relies	providing	the	requestor	with	information	to	
aid	 in	 the	assessment	of	 the	presence/absence	or	a	condition	or	progression/regression	of	a	
condition.	Assuming	the	test	has	value	to	the	requestor	when	the	test	is	being	made	how	does	
the	 result	 inform	 the	 requestor?	 This	 can	 only	 be	 through	 result	 interpretation,	 this	 is	 the	
added	value	step	that	turns	data	into	information	(2).		
	
Across	 Pathology	 the	 level	 of	 interpretation	 will	 vary	 according	 to	 speciality.	 The	 work	
undertaken	in	this	thesis	will	deal	specifically	with	the	field	of	Clinical	Biochemistry,	however	it	
is	recognised	that	all	specialities	in	Pathology	interpret	data	to	give	the	requestor	information.		
	
Interpretation	 could	 best	 be	 described	 as	 the	 contextualisation	 of	 variation	 of	 pathology	
results,	being	the	difference	between	an	expected	result	and	observed	result.	 	 In	 the	clinical	
setting	 results	have	variation	due	 to	 the	underlying	disease	process,	 this	 is	usually	described	
with	 reference	 to	 the	 variation	 from	 the	 reference	 range,	 using	 a	modified	 risk	 score	 or	 as	
variation	 from	 the	 previous	 result.	 More	 recently	 management	 of	 long	 term	 conditions	
increasingly	relies	on	changes	in	results	over	time,	which	can	be	as	part	of	complex	algorithms	
that	inform	clinical	decision	making.	This	is	seen	in	the	guidance	from	the	renal	registry	which	
defines	 the	 parathyroid	 hormone	 control	 as	 a	 marker	 of	 overall	 control	 of	 management	 of	
renal	 disease	 (3)	 or	 some	 algorithms	 for	 cardiovascular	 disease	 that	 use	 highly	 sensitive	 C-
reactive	protein	 in	 combination	with	HDL,	age	and	 smoking	 to	define	cardiovascular	 risk	 (4).	
Other	commonly	used	algorithms	include	Well’s	score	for	assessment	of	deep	vein	thrombosis	
and	estimated	glomerular	filtration	rate	(5).	It	is	extremely	important	to	stress	that	the	use	of	
algorithms	assumes	any	variation	in	result	is	due	to	the	physiological	condition	(6).	
	
Clinical	 laboratory	 tests	 are	 used	 to	 provide	 information	 that	 will	 help	 elucidate	 the	
pathophysiology	of	a	presenting	condition,	to	directly	manage	a	condition	based	on	a	series	of	
results	(give	drug	x	if	result	is	y)	or	to	assess	compliance	to	a	treatment	regime	(1).	When	the	
requesting	clinician	uses	the	information	from	laboratory	testing	or	laboratory	results	are	used	
in	 guidance,	 the	 variability	 seen	 is	 often	 assumed	 to	 be	 that	 which	 is	 associated	 with	 the	
pathophysiology	 and	 hence	 the	 variability	 due	 to	 non-pathophysiology	 reasons	 is	 often	
overlooked.	(7)		
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1.1 What	is	variation	in	the	context	of	laboratory	testing?	
	
The	 variability	 in	 test	 results	 will	 affect	 the	 result	 and	 therefore	 its	 interpretation,	 so	 it	 is	
essential	 to	 gain	 an	 understanding	 of	 the	 sources	 of	 variation	 that	 may	 ultimately	 affect	 a	
given	result	and	its	interpretation.	
	
Variation	in	results	is	made	up	from	variation	due	to	different	factors:	
a. the	pathophysiological	disease	process	
b. Variation	 due	 to	 non-pathophysiological	 disease	 processes	 that	 can	 usually	 be	
monitored	and	controlled.		
Non-pathophysiological	disease	processes	are	split	into	two	areas.	The	variation	observes	at	an	
individual	basis	and	the	variation	of	the	sample	process.	The	former	is	made	up	from	the	intra	
and	 inter-individual	 variation	 and	 the	 latter	 is	 made	 up	 from	 the	 pre,	 post	 and	 analytical	
variation	 (8).	 The	 non-pathophysiological	 variation	must	 be	minimised	 to,	 to	 ensure	 correct	
interpretation	of	variation	due	to	pathophysiological	process.	In	order	to	quantify	(and	hence	
minimise)	the	variation,	Fraser	et	al	(9)	described	the	Total	analytical	error	for	any	test	as	being	
the	 sum	 of	 the	 two	 times	 the	 random	 error	 (standard	 deviation),	 plus	 the	 systematic	 error	
(bias):	
	
TaE	=	bias	+	2	SD.	
TaE=	Total	analytical	error,	SD=	Standard	deviation	
	
Any	clinical	laboratory	will	strive	to	minimise	the	total	analytical	error,	which	is	determined	by	
both	bias	and	standard	deviation.	This	has	been	 further	developed	 into	 the	concept	of	Total	
allowable	error,	which	then	is	a	basis	for	setting	goals	for	performance	of	any	test	(10),	that	is	
to	minimise	both	the	standard	deviation	and	bias	in	any	laboratory	test.	
	
For	the	purposes	of	the	thesis,	I	am	not	considering	bias	(however	it	is	recognised	that	this	is	a	
significant	 source	 of	 error,	 especially	 when	 considering	 assay	 selection	 and	 calibration).	
Therefore,	the	focus	is	to	minimise	SD	as	a	marker	of	reduction	in	variation.		
What	 does	 this	 mean	 in	 reality?	 If	 variation	 is	 considered	 from	 the	 perspective	 of	 Clinical	
Biochemistry,	there	is	a	continuous	fluctuation	of	biochemical	markers	in	biological	fluids,	this	
is	best	described	in	terms	of	biological	variation	(CVi)	
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The	CVi	of	analytes,	in	biological	fluids,	is	of	three	types	(11):	
1. Variation	over	the	life	span	of	the	analyte,	eg	half	life	
2. Cyclical	variation,	eg	due	to	circadian	rhythm	
3. Random	variation.	
CVi	can	be	between	groups	of	patients,	for	example	in	comparing	HbA1c	in	a	diabetic	and	non	
diabetic	population,	which	is	often	used	for	diagnosis,	or	it	can	within	an	individual	where	for	a	
diabetic	 patient	 HbA1c	 is	 used	 serially	 to	 monitor	 glycaemic	 control.	 Hence	 it	 is	 important	
when	looking	at	the	purpose	of	the	test,	whether	it	is	for	monitoring	progress	or	regression	of	
a	condition	 in	an	 individual	or	use	of	a	 test	 for	diagnosis,	where	the	result	will	be	compared	
against	population	norms.	
	
The	 other	 component	 of	 variation	 in	 pathology	 testing	 is	 the	 analytical	 error,	which	 can	 be	
minimised	and	controlled,	using	tools	described	in	page	13.	This	is	especially	important	if	it	is	
considered	that	the	error	due	to	CVi	 is	difficult	 to	minimize.	The	analytical	variability	 (Cva)	 is	
therefore	kept	appropriately	 less	 than	 the	biological	 variability	 for	 the	 test	 to	be	confidently	
used	for	clinical	diagnosis	and	monitoring	(12).		
	
As	discussed	earlier	the	concept	of	Total	allowable	error	provides	a	guideline	on	performance	
of	 a	 test.	 However	 that	 is	 of	 limited	 use	 when	 considering	 the	 purpose	 of	 test,	 the	 below	
equation	calculates	the	significance	of	the	change	in	results	or	reference	change	value	(RCV),	
taking	into	account	both	the	analytical	and	individual	variation:		
	
RCV	=	√2	*Z*√CVa2+CVi2	
	
CVa	 =	 analytical	 imprecision,	 CVi	 =	 Biological	 variation,	 Z	 =	 Z	 value	 (1.96	 for	 p<0.05	 or	
95%probablity)	
	
In	calculation	of	the	RCV,	it	is	acknowledged	that	to	have	a	significant	change	in	a	result,	one	
must	 take	 into	 account	 both	 the	 analytical	 and	 biological	 imprecision.	 Therefore	 Clinical	
laboratories	must	ensure	that	CVa	and	CVi	are	minimised		so	that	any	change	articulated	by	a	
change	 in	 RCV	 is	 predominantly	 due	 to	 changes	 in	 pathophysiology.	 Examples	 of	 common	
analyte	RCVs	under	current	analytical	conditions	are,	C-Reactive	protein	206%,	Creatine	kinase	
119%,	 TSH	 104%.	 Clearly	 the	 variation	 due	 to	 non-physiological	 processes	 is	 significant	 and	
should	be	minimised	(13).	However,	in	order	to	minimise	it,	one	has	to	have	an	understanding	
of	the	contributory	sources	of	variation.	
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1.2 Sources	of	variation	
	
The	 potential	 sources	 of	 error	 in	 the	 whole	 process	 of	 Pathology	 requesting	 to	 testing	 and	
interpretation	 is	 best	 described	 through	 the	 Brain-to-Brain	 Loop	 Concept	 for	 Laboratory	
testing	 in	 which	 Lundberg	 (14)	 introduced	 the	 concept	 of	 the	 thought	 of	 requesting	 an	
investigation	being	generated	in	the	brain	of	the	clinician	caring	for	the	patient	through	to	the	
result	 affecting	 a	 future	 decision	 on	 the	 patient	 to	 be	made	 by	 the	 clinician.	 The	 first	 step	
involves	the	selection	of	laboratory	tests	and	the	final	step	is	the	transmission	of	the	test	result	
to	the	ordering	physician.		
	
Figure	1.1		Adapted	version	of	the	Lundbergs	brain	to	brain	cycle	
	
	
The	 introduction	of	 this	 concept	 led	 to	a	 system	 to	 identify	 and	 classify	 errors	 associated	of	
laboratory	 test	 performance,	 namely	 pre-analytic,	 analytic,	 and	 post-analytic	 errors.	 These	
definitions	 still	 hold	 true	 four	 decades	 later,	 however	more	 recently	 Plebani	 et	 al	 (15)	 have	
identified	 further	 modifications	 in	 consideration	 of	 the	 test	 and	 its	 eventual	 outcome,	 the	
addition	of	point	of	care	testing	and	the	advent	of	molecular	medicine.	I	would	like	to	add	an	
additional	source	of	variation	that	is	not	often	considered,	this	is	selection	of	an	inappropriate	
test	 for	 that	 which	 is	 being	 investigated.	 This	 was	 clearly	 shown	 in	 my	 collaborative	 first	
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published	paper	on	 laboratory	processes,	where	I	described	the	 inappropriate	use	of	glucose	
meters	 to	 diagnose	 hypoglycaemia	 and	 the	 consequences	 of	 the	misdiagnosis	 that	 followed	
(16).	
	
It	must	be	emphasised	that,	where	possible,	the	responsibility	of	the	laboratory	professional	to	
minimise	these	sources	of	variation,	to	allow	for	results	to	accurately	reflect	the	variation	due	
to	the	presence	or	change	in	disease	pattern.		
	
The	proportion	of	each	of	the	three	main	types	of	error	is	shown	in	figure	1.2	as	described	by	
Carraro	and	Plebani	(17),	pre-analytical	being	the	greatest	at	62%	of	the	total	errors,	analytical	
23%	and	post	analytical	15%.	This	audit	study	was	based	on	observed	error	rates	across	four	
hospital	 departments,	 where	 the	 clinical	 teams	 notified	 the	 laboratory	 of	 questionable	
findings.	
	
Figure	1.2		Proportion	of	errors	associated	with	laboratory	testing.	
	
A	 further	 source	of	variation	 is	 the	post/post	analytical	phase,	which	 is	 the	part	of	 the	cycle	
that	 deals	 with	 the	 results	 being	 inadequately	 followed	 up	 of	 dealt	 with	 by	 the	 requesting	
physician	(18)	
	
Before	 discussing	 the	 component	 parts	 of	 variation	 it	 is	 important	 to	 understand	 that	 the	
relative	contribution	of	each	form	of	variation	will	change	according	to	time	and	according	to	
the	assays	used.	 For	example	 in	 the	1980s	 the	 contribution	of	 analytical	 variation	was	more	
significant	as	assay	performance	was	poor	with	common	endocrine	tests	having	CVs	of	up	to	
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25%.	However,	presently,	pre-analytical	variation	is	the	most	significant	source	of	error	as	the	
variables	associated	with	it	are	difficult	to	quantify	and	control	(18).	In	my	view	it	is	likely	that,	
as	testing	complexity	increases,	the	significant	errors	will	be	post-	analytical	(19).	
		
1.2.1 Analytical	variation	
	
The	 variability	 seen	 in	 the	 analytical	 phase	 is	 well	 documented	 (20).	 This	 could	 arise	 from	
equipment	 breakdown	 or	 malfunction,	 sample	 mix	 ups,	 interference	 or	 poor	 analytical	
performance	as	demonstrated	through	failure	in	quality	control.	It	is	summarised	as	variation	
due	to	analytic	process	variability.	It	is	the	job	of	the	laboratory	to	eliminate	and	if	that	is	not	
possible	 to	 understand	 each	 possible	 source	 of	 variation.	 There	 are	 many	 tools	 used	 to	
highlight	and	minimise	laboratory	variation:	
	
1.	 Internal	quality	control	to	assess	intra-laboratory	analytical	variation	
2.	 Analyte	External	quality	control	(EQA)	to	assess	lab	to	lab	variation	
3.	 UKAS/ISO15189	(2012).	For	Pre-analytical,	analytical	and	post	analytical	
4.	 Continuing	personal	development	of	laboratory	staff	
5.	 Harmonisation	of	practice	and	protocols	
	
Analytical	 variation	 is	 the	 component	 of	 variation	 that	 is	 in	 many	 ways	 easier	 to	 identify	
(through	the	above	means)	and	the	process	by	which	variation	is	identified	is	tried	and	tested	
(21).	 The	 tools	 and	principles	of	 assessment	 and	 control	 have	 remained	 constant	 and	 in	 the	
last	30	years	(22),	although	the	methods	have	changed.		
	
1.2.2 Post-analytical	variation	
	
Although	 variation	 does	 occur	 in	 this	 phase,	 it	 is	 likely	 to	 be	 based	 on	 the	 interpretation	 of	
results,	rather	than	the	generation	of	results.	Such	errors	would	include	erroneous	validation	
of	 analytical	 data,	 failure	 in	 reporting,	 excessive	 turnaround	 time,	 improper	 data	 entry	 and	
manual	 transcription	 errors	 and	 failure	 /delay	 in	 reporting	 critical	 values.	 	 So	 in	 order	 to	
interpret	results	adequately	it	is	for	the	Clinical	laboratory	staff	to	ensure	that	such	variation	is	
minimised	and	to	interpret	the	result	in	the	light	of	the	remaining	variation	i.e.	is	it	related	to	a	
change	in	the	underlying	condition?		
The	 following	 are	 routinely	 used	 to	 understand,	 control	 and	 minimise	 the	 post	 analytical	
variation	(ref):	
1. National	EQAS	for	interpretative	comments	
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2. Continuous	personal	development	
3. Discrepancy	meetings	where	reporting	difference	are	discussed,	these	could	be	raised	
at	MDT	for	example	
4. Education	in	attending	conferences	and	clinical	meetings	
By	quantifying	the	post	analytical	variation	it	 is	possible	to	limit	the	effects	by	setting	targets	
for	improvement	through	the	above	processes.		
	
1.2.3 Pre-analytical	variation		
	
Pre-analytical	variation	is	the	most	significant	component	of	total	variation	which	was	also	the	
most	 difficult	 to	 quantify.	 Therefore,	 a	 categorisation	 of	 the	 variation	 leads	 to	 an	 improved	
understanding	and	ultimately	to	a	mitigation	of	the	risk	associated	with	the	variation	(through	
a	change	in	process	or	better	understanding)	
	
The	constituent	parts	of	pre-analytical	variability	(23),	some	of	which	have	are	investigated	in	
the	papers	submitted	in	this	thesis,	are	shown	below:	
1. Variability	due	to	intrinsic	physiology	
a. Age	
b. Sex	
c. Race	
d. Circadian	rhythm	
2. Variability	due	to	life	style	
a. Diet,	including	alcohol,	caffeine,	calorific	intake	
b. Behaviour,	including	smoking,	exercise,	stress	
c. Posture	
3. Variability	due	to	inappropriate	test	selection	
4. Variability	due	to	disease	process	
5. Variability	due	to	concurrent	conditions,	which	cause	 interference	with	analytical	
process	
a. Liver	disease	causing	raised	bilirubin	
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b. Hyperlipidaemia		
c. Haemolysis	
d. Hyperproteinaemia	 	
6. Variability	due	to	phlebotomy	affecting	haemostasis	
7. Variability	due	to	in	vivo	drug	interactions	
8. Variability	due	to	in	vitro	sample	tube	collection	(including	anticoagulant)	
9. Variability	due	to	sample	transport	and	storage.	
	
The	question	 to	be	asked	 is	what	 is	done	with	 the	 information	on	variation?	The	risk	due	 to	
pre-analytical	error	 is	understood	and	there	are	 the	tools	 to	detect	and	quantify	 it,	however	
the	 clinical	 laboratory	must	 also	 set	 standards	 to	minimise	 the	 risk,	whether	 that	 is	 through	
defining	 fasting/non	 fasting	 or	 samples	 taken	 at	 a	 specific	 time	 of	 the	 day,	 it	 could	 be	
producing	 clear	 guidance	 on	 sample	 tube	 type	 to	 use	 for	 phlebotomy	 or	 understanding	
complex	drug	interactions.		
	
We	must	 set	 standards	 for	 reduction	 in	errors	and	key	performance	 indicators	 to	 reflect	 the	
complexity	 of	 error,	 only	 then	 can	 the	 error	 be	 reduced	 through	 standardisation	 and	
education.	Westgard	 has	 established	 a	 data	 base	 on	 desirable	 specifications	 for	 Total	 Error,	
Imprecision,	 and	 Bias,	 derived	 from	 intra-	 and	 inter-individual	 biologic	 variation,	 this	 is	 an	
invaluable	tool	when	considering	variation	in	the	pre-analytical	phase	(24).	
	
The	 work	 I	 have	 carried	 out	 in	 this	 thesis	 has	 been	 to	 elucidate	 the	 variability	 due	 to	 pre-
analytical	 sources,	 which	 include	 elements	 of	 the	 intra	 and	 inter	 individual	 variability.	 The	
purpose	was	to	identify	the	sources	of	variability	that	may	affect	the	interpretation	of	certain	
analytes	 that	 were	 in	 use	 at	 the	 time.	 The	 analytes	 were	 selected	 due	 to	 their	 potential	
influence	on	medical	practice	and	therefore	at	the	time	the	work	was	both	timey	and	relevant.	
However	 the	 scientific	 principles	 behind	 the	 hypothesis	 was	 and	 is	 of	 importance,	 as	 all	
methods	must	be	assessed	for	their	variabilities	(25).		Much	of	my	research	has	focused	on	the	
identification	 of	 and	 mitigation	 of	 the	 pre-analytical	 variability	 in	 common	 Clinical	
Biochemistry	 tests.	 The	 propose	 of	 this	 is	 to	 quantify	 some	 of	 the	 components	 of	 variation	
inherent	in	laboratory	testing,	in	order	to	minimise	where	possible	and	educate	the	individuals	
the	interpret	the	laboratory	results	for	the	requesting	clinicians,	the	papers	I	have	written	have	
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been	cited	147	times	detailed	in	section	3),	demonstrating	a	dissemination	of	knowledge	and	
good	working	practices.	
	
Specifically	 I	have	published	 in	 relation	 to	 the	effect	of	patients	ethnicity	 (26-27),	underlying	
concurrent	 conditions	 (28-30),	 patient	preparation	prior	 to	blood	 sampling,	 venesection,	 the	
sample	tube	the	blood	is	drawn	into	and	effects	of	anticoagulants	and	clot	separators	(31-35),	
physiological	 interferants	 in	 the	 sample	 that	 affect	 the	 result,	 i.e.	 lipaemia,	 haemolysis	 and	
icteric	 samples	 (36)	 and	 the	 effect	 of	 the	 point	 of	 care	 testing	 on	 result	 reliability	 for	
interpretation	(16).	My	work	provides	clear	evidence	that	there	 is	considerable	variation	due	
to	the	above	factors	and	these	must	be	understood	if	one	is	to	make	an	adequate	assessment	
of	Clinical	Biochemistry	results	in	relation	to	the	presenting	clinical	information.	
	
The	work	 I	have	completed	has	 lent	significant	weight	 to	the	understanding	of	pre-analytical	
variability.	Unfortunately	there	is	no	substitution	for	an	in	depth	understanding	of	the	sources	
of	variability,	even	if	one	was	able	to	quantify	the	extent	of	the	variation,	the	range	and	type	of	
pre-analytical	variability	are	so	numerous	that	this	would	be	a	meaningless	exercise.	
	
It	 is	 important	 to	 recognise	 that,	 although	 these	papers	were	published	 some	 time	ago,	 the	
techniques,	 the	mathematics	 and	 the	principles	of	 investigation	are	as	 relevant	now	as	 they	
were	at	the	time	of	my	earliest	publication	
	
1.3 Research	questions	
	
There	are	three	main	areas	of	study	that	 form	the	basis	of	 the	 investigations	supporting	this	
thesis,	in	addition	there	are	two	further	papers	that	describe	variation	outside	the	three	main	
areas,	which	none	the	less	also	describe	important	sources	of	variation.	
	
Project	1:	This	project	studies	into	the	in	vitro	stability	of	analytes	post	venesection.		
	
This	 is	 an	 extremely	 important	 area	 of	 investigation,	 as	 the	 laboratories	 I	 currently	work	 in	
receive	approximately	10	000	 samples	per	day.	 Those	analytes	 requested	may	be	 subject	 to	
degradation	 due	 to	 metabolic	 process	 in	 the	 sample,	 which	 can	 be	 inhibited	 by	 various	
stabilisation	 agents	 in	 the	 tube	 or	 by	 variation	 in	 the	 conditions	 in	 which	 the	 tube	 is	
transported	such	as	time,	temperature	and	atmospheric	pressure.	Specifically	I	looked	at	two	
analytes	parathyroid	hormone	(PTH)	and	C-Reactive	protein	(CRP).	PTH	was	selected	for	study	
as	 this	 is	a	 labile	protein	used	 in	 the	assessment	of	bone	disease.	 It	used	as	a	marker	 in	 the	
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differential	diagnosis	of	calcium	metabolism,	this	was	an	important	area	of	research	activity	as	
PTH	 was	 being	 used	 as	 a	 marker	 of	 calcium	 homeostasis	 by	 the	 Renal	 Registry	 (37)	 with	
increased	variation,	against	prescribed	 limits,	being	attributed	to	poor	management	CRP	was	
selected	 as	 it	 was	 proposed	 as	 a	 novel	 marker	 of	 cardiovascular	 disease,	 however	 the	
measurement	 was	 both	 technically	 difficult	 and	 thus	 challenging	 to	 interpret	 (38).	 It	 was	
important	 to	assess	 the	 contribution	of	pre-analytical	 variation	 to	 the	 small	 changes	 seen	 in	
CRP	concentrations	and	to	assess	the	effectiveness	of	the	marker	in	that	light.	
	
Project	 2:	 This	 project	 studied	 the	 intra	 individual	 variation	 in	 laboratory	 analytes	 due	 to	
ethnicity.			
	
Specifically	there	were	three	areas		studied.	I	investigated	whether	there	was	ethnic	variation	
in	total	cholesterol	and	HDL.	Ethnicity	as	a	component	of	any	population	varies,	therefore	with	
the	use	of	algorithms	such	as	The	Sheffield	tables	(39),	whether	such	variation	described	could	
be	due	to	ethnicity	rather	than	pathophysiological	reasons.	I	also	studied	the	ethnic	variation	
in	CRP,	as	CRP	was	proposed	as	a	marker	in	cardiovascular	risk	assessment.	Finally	I	wanted	to	
assess	whether	there	was	maternal	variation	of	B12	in	white	Caucasians	living	in	the	UK	
	
Project	3:	Variation	in	laboratory	results	due	to	a	pre-existing	condition	causing	an	elevation	in	
interfants.			
	
This	 work	 assessed	 three	 areas,	 initially	 I	 investigated	 the	 effect	 of	 lipaemia	 on	 other	
commonly	 requested	 tests.	 Lipaemia	 is	 a	 potential	 interference	 in	 many	 photometric	 and	
colorimetric	assays	commonly	used	 in	 the	 laboratory.	 I	wished	 to	 test	whether	 the	potential	
interference	 that	 is	 frequently	 reported,	does	 in	effect	 cause	a	 variation	 in	 results.	 Secondly	
was	the	hyperprolactinaemia	observed	 in	rheumatoid	arthritis	genuine	or	 laboratory	artefact	
and	 finally	a	 series	of	case	histories	 investigated	pseudo-pseudo	hypercalcaemia	observed	 in	
Waldenstroms	macroglobulinaemia,	as	a	significant	cause	of	variation	that	could	lead	to	over	
investigation.	
	
Additional	studies:	 Investigated	how	the	high	variability	 in	CRP	would	render	 it	 ineffective	 in	
its	 incorporation	 into	 coronary	 heart	 disease	 risk	 assessment,	 this	 bought	 together	 previous	
observations	around	the	pre-analytical	variation	and	variation	due	to	ethnicity.	My	final	study	
for	 inclusion	 was	 the	 effect	 of	 inappropriate	 equipment	 selection	 for	 the	 diagnosis	 of	
hypoglycaemia	 and	 how	 it	 can	 lead	 to	 inaccurate	 results	 and	 therefore	 unnecessary	
investigations.		 	
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1.4 Relevance	of	studies	and	findings	to	current	approaches	to	minimising	pre-
analytical	variation	
	
Pre-analytical	 variation	 has	 and	 always	 will	 be	 a	 component	 of	 non-pathological	 variation,	
which	is	in	turn	part	the	total	variation	seen	in	pathology	testing,	as	articulated	by	Compton	in	
Garbage	 in,	Garbage	out	 (40).	 The	mathematics	 underpinning	 the	quantification	of	 variation	
are	constant	and	are	articulated	 in	chapter	1.1,	these	have	not	varied	over	the	 last	40	years.	
However	Simundic	et	al	(41)	have	recently	refined	definitions	and	nomenclature	to	standardise	
the	laboratory	approach	to	quantification	of	variation.	
		
The	 constituent	 parts	 of	 non-pathological	 variation	 are	 detailed	 in	 chapter	 1.2,	 as	
demonstrated	in	Lundberg’s	brain	to	brain	cycle	first	put	forward	in	the	1970s	(14).	These	have	
been	modified	by	Plebani	et	al	in	2012	(15),	to	include	new	development	in	diagnostics	such	as	
point	of	 care	 testing	and	molecular	 testing.	These	novel	areas	are	of	 increasing	 relevance	 to	
clinical	 pathology	 testing	 as	 evidenced	 by	 the	 rise	 in	 one	 stop	 clinics	 and	 personalised	
medicine.	Plebani’s	work	also	demonstrates	the	enduring	nature	of	pre-analytical	variability	in	
total	 variation,	 however	 it	 is	 recognised	 that	 over	 time	 as	 the	 emphasis	 on	 testing	 and	
technologies	changes,	the	significance	of	the	various	constituent	parts	may,	in	it	self,	vary.	For	
example,	a	significant	source	of	pre-analytical	variation	in	glucose	measurement	by	laboratory	
is	the	time	to	stabilisation	of	the	sample,	whereas	with	point	of	care	glucose	testing,	time	to	
analysis	is	minimal,	however	method	variation	is.	
		
The	work	I	have	carried	out	was	relevant	for	those	assays	and	the	application	of	those	assays	
at	the	time	and	still	have	relevance	as	long	as	those	assays	are	in	use.		However	the	principles	
still	 hold	 relevance	 as	 demonstrated	 through	 the	 UKAS	 ISO	 15189	 standards	 for	 laboratory	
testing,	specifically	clause	5.4,	pre	examination	processes,	which	articulates	 the	need	for	 the	
laboratory	to	understand	the	pre-analytical	variables	associated	with	an	assay	(25).	Therefore	
the	use	of	 the	techniques	 I	have	used	 in	this	work	are	relevant	to	current	practice	and	must	
still	be	used	in	the	assessment	of	new	assays	and,	most	importantly,	the	variation	associated	
with	the	assays	must	be	quantified	and	used	in	the	interpretation	of	the	total	variation	in	any	
result.	
		
Another	example	of	the	importance	of	an	understanding	of	preanalytical	variation	is	to	provide	
evidence	 to	 support	 the	 change	 in	 delivery	 of	 pathology.	 NHSi	 have	 recently	 published	
recommendations	around	optimal	configuration	of	pathology	laboratories	(42),	suggesting	that	
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large	 networks	 should	 be	 formed,	 with	 the	 majority	 of	 work	 being	 undertaken	 in	 factory	
laboratories.	 In	 order	 to	 facilitate	 that,	 pathology	 samples	 will	 have	 to	 be	 transported	 long	
distances.	 Therefore	 pathology	 laboratories	 must	 understand	 the	 effect	 of	 transport,	
temperature	and	 time	 to	 stabilisation	on	 the	assays	 it	offers,	 if	 they	are	 to	offer	 those	 tests	
from	the	 factory	 laboratory.	This	demonstrates	 the	value	of	 the	 investigations	 I	have	carried	
out	on	PTH	and	CRP	stability	and	highlights	possible	areas	for	future	research.	
		
Further	areas	of	research	would	be	in	the	emerging	technologies	being	used	in	the	laboratory	
such	 as	 point	 of	 care	 testing	 and	 molecular	 testing,	 where	 an	 understand	 of	 the	 non-
pathological	variation	is	essential	to	the	interpretation	of	any	test.	Another	interesting	area	of	
work	 is	 in	algorithm	development,	where	groups	of	 tests	are	used	 to	determine	change	 in	a	
condition,	however,	often	the	role	of	pre-analytical	variation	is	ignored	or	underestimated.	
		
In	 summary	 the	work	undertaken	 in	 this	 thesis	 is	 relevant	 for	 those	assays	 studied,	as	 those	
assays	are	still	in	use.	The	principles	of	investigation	are	relevant	for	all	assays,	given	the	UKAS	
guidance	and	there	is	significant	research	to	do	looking	at	novel	techniques	and	applications	in	
the	laboratory.		The	purpose	of	any	work	undertaken	must	support	the	purpose	of	this	work,	
to	identify	and	reduce	non-pathological	variation	to	inform	result	interpretation.	
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Chapter	2 Commentary	 linking	 the	 published	 work	 to	 the	 studies	
outlined	in	the	previous	chapter	
	
2.1 Project1.	Studies	into	the	in	vitro	stability	of	analytes	post	venesection.		
	
Analytes	may	be	subject	to	degradation	due	to	metabolic	process	in	the	sample,	which	can	be	
inhibited	by	various	stabilisation	agents	in	the	tube	or	by	variation	in	the	conditions	in	which	
the	 tube	 is	 transported	 such	 as	 time,	 temperature	 and	 atmospheric	 pressure.	 The	 research	
questions	 I	 studied	were,	whether	 there	 are	 significant	 pre-analytical	 variations	 observed	 in	
the	laboratory	testing	process,	and	could	this	affect	the	utility	of	the	test.	Specifically	I	looked	
at	two	analytes	parathyroid	hormone	(PTH)	and	C-Reactive	protein	(CRP).	
	
2.1.1 Study	1.	
My	first	 investigation	was	 into	the	effect	of	a	protease	 inhibitor	on	 in	vitro	stability	of	 intact	
parathyroid	 hormone.	 Previous	 studies	 on	 intact	 parathyroid	 hormone	 (iPTH)	 have	 reported	
that	any	in	vitro	degradation	of	iPTH	in	unseparated	blood	samples	may	be	sample	tube-	and	
time-dependent	 (43-44).	 The	 greater	 degradation	 of	 iPTH	 observed	 in	 serum	 compared	 to	
EDTA	 plasma	 (45)	 remains	 unexplained.	 Increased	 in	 vitro	 degradation	 of	 iPTH	 has	 been	
reported	in	patients	who	have	high	concentrations	of	circulating	proteases	(46).	Additionally,	it	
has	been	demonstrated	that	the	addition	of	protease	inhibitors	may	arrest	the	in	vitro	decline	
in	 iPTH	 over	 24h	 (47),	 but	 this	may	 be	 assay-	 and	 sample	 population	 dependent.	 Thrombin	
plays	a	significant	in	vivo	role	in	platelet	aggregation	as	part	of	the	clotting	process.	Initiation	
of	platelet	aggregation	requires	protease-dependent	binding	of	thrombin	to	platelet	thrombin	
receptors	 (48).	 This	 increase	 in	 protease	 activity	 may	 be	 responsible	 for	 the	 in	 vitro	
degradation	 of	 PTH.	 I	 therefore	 investigated	 whether	 the	 addition	 of	 aprotinin	 (a	 potent	
protease	inhibitor)	influenced	the	in	vitro	stability	of	serum	iPTH	in	unseparated	samples	from	
patients	with	chronic	renal	disease.	
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2.1.1.1 Materials	and	methods	
	
We	 venesected	 11	 patients	with	 chronic	 renal	 failure	 prior	 to	 them	 receiving	 dialysis.	 Blood	
samples	were	collected	into	10-mL	plain	glass	tubes	(Z10/GN,	LIP	Equipment	and	Services	Ltd,	
Shipley,	UK),	with	and	without	2000	KIU	of	aprotinin	(Bayer	AG,	Germany),	and	2.7-mL	EDTA	
tubes	 (Sarstead	Monovet	2.7	mL	KE,	Aktiengesellschaft	&	Co,	Germany).	 Samples	were	 then	
transported	 to	 the	 laboratory	 on	 ice	 and	 remained	 unseparated	 at	 room	 temperature	 (17–
23°C)	until	centrifugation.	At	20	min	(baseline),	1h,	2	h,	4	h,	8	h	and	24	h,	a	1-mL	aliquot	was	
taken	 from	each	 tube	and	 centrifuged.	 The	 resultant	 supernatant	was	 frozen	at	–	20°C	until	
analysis,	which	was	 carried	out	 in	one	batch	using	 the	DPC	 Immulite	 iPTH	assay	 (intra-assay	
coefficient	 of	 variation	 4.8)	 (LKPH,	 Diagnostic	 Products	 Corporation,	 Los	 Angeles,	 CA,	 USA)	
immediately	 following	thawing	of	 the	aliquot.	Following	 logarithmic	transformation,	 the	data	
were	 normally	 distributed.	 Statistical	 analysis	 of	 the	 transformed	 data	 was	 by	 parametric	
repeat	measures	ANOVA	with	Tukey–Kramer	post-test	 comparison.	Results	are	given	as	pre-
transformed	data	expressed	as	median	(95%	confidence	intervals).	
	
2.1.1.2 Results	
	
Concentrations	 of	 iPTH	 in	 each	 tube	 type	 over	 time	 are	 shown	 in	 Table	 2.1.	 The	 iPTH	
concentration	 in	 the	 plain	 sample	 separated	 at	 24	 h	 was	 significantly	 lower	 than	 in	 those	
separated	at	baseline	(P<0.001),	1.h	(P<0.001),	2	h	(P<0.001),	4	h	(P<0.001)	and	8	h	(P<0.001).	
There	were	no	significant	differences	between	any	other	time	points.	Between	baseline	and	24	
h	 the	 decline	 in	 iPTH	 in	 plain	 tubes	 was	 24.7%.	 The	 iPTH	 value	 in	 the	 aprotinin	 sample	
separated	 at	 24h	 was	 significantly	 lower	 than	 those	 separated	 at	 baseline	 (P<0.01),	 1	 h	
(P<0.001),	2	h	(P<0.001),	4	h	(P<0.001)	and	8	h	(P<0.001).	There	were	no	significant	differences	
between	 any	 other	 time	points.	 Between	baseline	 and	 24	 h	 the	 decline	 in	 iPTH	 in	 aprotinin	
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tubes	was	9.6%.	There	were	no	differences	in	iPTH	concentrations	between	the	EDTA	samples	
separated	 at	 any	 time	point.	 iPTH	 concentration	was	 significantly	 lower	 in	plain	 tubes	when	
compared	 with	 aprotinin	 tubes	 (P<0.05)	 at	 24	 h.	 iPTH	 concentration	 was	 also	 significantly	
lower	in	plain	tubes	(P<0.001)	and	aprotinin	tubes	(P<0.01)	when	compared	with	EDTA	tubes	
at	24	h.	There	were	no	other	significant	between-tube	differences	at	any	other	time	points.	
	
	 Tube	Type	
Time	
(h)	
Number	 of	
Samples	
Plain	 Aprotinin	 EDTA	
0.3	
1	
2	
4	
8	
27	
11	
11	
11	
11	
11	
11	
46.5	(20.2-62.4)	
51.7	(20.6-61.4)	
47.3	(19.9-61.7)	
46.6	(20.9-65.3)	
46.6	(20.2-62.9)	
30.7ᶧᶧ	(13.9-48.5)	
43.7	(19.1-61.8)	
45.8	(20.4-60.0)	
48.9	(23.3-62.5)	
47.4	(20.7-64.2)	
45.0	(20.6-64.4)	
34.3ᶧ,	C*	(16.9-56.4)	
51.3	(20.7-65.6)	
45.8	(20.6-62.5)	
52.4	(21.6-63.4)	
50.8	(20.9-67.1)	
53.3	(22.2-67.8)	
49.2	(A**,	b**	(19.9-63.9)	
	
Table	 2.1	 Intact	 parathyroid	 hormone	 concentrations	 (pmol/L)	 in	 different	 sample	 tubes	
against	time.	
	
Results	 are	 median	 (95%	 confidence	 limits).	 Within-tubes,	 the	 only	 significant	 differences	
observed	compared	with	baseline	(0.3	h)	were	at	24	h:ᶧP<0.01,	ᶧᶧP<0.001.		Between-tubes,	the	
only	 significant	 differences	 were	 observed	 at	 24	 h:	 a,	 EDTA	 compared	 to	 plain	 tube,	
***P<0.001;	 b,	 EDTA	 compared	 to	 aprotinin	 tube,	 **P<0.01;	 c,	 aprotinin	 tube	 compared	 to	
plain	tube,	*P<0.05.	
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2.1.1.3 Summary	and	significance	
	
The	unchanged	plasma	iPTH	concentrations	in	EDTA	tubes,	 left	unseparated	for	up	to	24	h	in	
pre-dialysis	 samples	 collected	 from	patients	with	 chronic	 renal	 failure,	 confirms	 that	 iPTH	 is	
stable	 for	 up	 to	 24	 h	 in	 unseparated	 EDTA	 samples	 (49).	 Although	 I	 found	 no	 significant	
difference	 in	 baseline	 results	 between	 any	 of	 the	 tubes,	 Omar	 et	 al.	 reported	 significantly	
higher	 baseline	 iPTH	 values	 in	 EDTA	 tubes	 compared	 with	 plain	 tubes	 in	 samples	 collected	
from	patients	attending	a	renal	stone	clinic	(50).	These	differences	could	be	explained	by	the	
different	mixture	 of	 PTH	 fragments	 in	 each	 of	 the	 different	 sample	 populations,	which	may	
have	different	in	vitro	stability.	
	
In	 this	 study,	 serum	 iPTH	concentrations	were	stable	when	 left	unseparated	 for	up	 to	8	h	 in	
plain	 and	 aprotinin-containing	 tubes.	 The	 addition	 of	 aprotinin	 to	 plain	 tubes	 significantly	
reduced	the	decline	 in	 iPTH	at	24	h.	However,	 there	was	still	 significant	difference	 in	 iPTH	 in	
aprotinin	 tubes	 when	 compared	 with	 EDTA	 tubes	 at	 24	 h.	 Levin	 and	 Nesbit(44)	 using	 the	
Nichols	Institute,	Allegro	iPTH	assay,	found	that	addition	of	two	protease	inhibitors	(aprotinin	
and	leupeptin)	eliminated	the	decline	in	iPTH	that	I	observed	at	24	h	when	compared	to	EDTA	
tubes.	 It	 is	 possible	 that	 the	 combination	 of	 protease	 inhibitors	 confers	 greater	 protection	
against	 in	 vitro	 iPTH	 instability.	 However,	 as	 both	 studies	 used	 different	 iPTH	 assays	 and	
different	study	populations,	this	is	not	clear.	
	
My	findings	suggest	that	increased	protease	activity	could	explain,	in	part,	the	decline	in	serum	
iPTH	 in	 blood	 samples	 left	 unseparated	 for	 greater	 than	 8	 h.	 Aprotinin	 is	 a	 serine	 protease	
inhibitor	and	probably	acts	in	vivo	by	inhibiting	the	thrombin	induced	proteolytic	activation	of	
platelets	 (47).	 This	 mechanism	 may	 explain	 the	 in	 vitro	 observation	 that	 iPTH	 decline	 is	
observed	 in	 serum	 and	 not	 in	 EDTA	 plasma,	 suggesting	 that	 the	 increased	 protease	 activity	
may	be	due	 to	 the	 clotting	 process.	 Plain	 and	 EDTA	 tubes	 are	 appropriate	 sample	 tubes	 for	
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collection	of	 iPTH	 in	patients	with	 renal	disease,	 if	 left	unseparated	 for	up	 to	8	h.	 Increased	
protease	 activity	 may	 solely	 or	 partially	 contribute	 to	 the	 decline	 in	 serum	 iPTH	 in	 blood	
samples	left	unseparated	for	longer	than	8	h.	
	
2.1.2 Study	2.		
	
I	compared	the	stability	of	IPTH	in	blood	samples	taken	into	gel	tubes	(Sarstead	Monovet	4.7	
mL,	Z	GEL)	and	plain	glass	tubes	(Lip	Z10/GN).	
	
2.1.2.1	Materials	and	methods	
Blood	 was	 drawn	 from	 nine	 patients	 with	 chronic	 renal	 failure	 before	 commencement	 of	
haemodialysis.		Immediately	after	venesection,	samples	were	split	between	the	plain	and	the	
gel	tubes.		Samples	were	then	separated	after	20	min	at	room	temperature	and	serum	frozen	
at	 -20⁰C	until	 assayed	 for	 iPTH	using	 the	DPC	 Intact	PTH	assay	on	 the	 Immunlite	automated	
immunoassay	analyser.			
	
2.1.2.2	Results	
Intact	 PTH	 values	 were	 13%	 higher	 (P<0.01,	 two-tailed	 paired	 t-test)	 in	 plain	 serum	 tubes	
[mean	(SD):	7.6	(2.57)	pmol/L]	than	in	gel	serum	tubes	[6.7	(2.19)	pmol/L],	as	shown	in	figure	
2.1.	
	
	
	
Figure	2.1		Stability	of	intact	PTH	at	room	temperature	in	plain	serum	tubes	(1)	and	gel	tubes	
(2).	All	samples	separated	by	20	min	and	serum	stored	at	–	20	until	analysis	
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2.1.2.3	Summary	and	significance	
I	 suggest	 that	 these	 differences	 in	 iPTH	 values	 are	 attributable	 to	 the	 gel	 barrier	 or	 clot	
activator	or	both,	especially	 since	 these	 results	are	consistent	with	other	 studies	 reporting	a	
similar	‘gel	effect’	on	other	immunoassays	(49).	
	
DPC	 also	 recommended	 that	 blood	 samples	 when	 collected	 into	 EDTA	 should	 fill	 the	 tube.		
Otherwise,	 the	EDTA	concentration	 in	 the	sample	will	proportionately	 increase,	affecting	 the	
Immulite	substrate	alkaline	phosphatase	reaction	and	thus	lowering	the	iPTH	result.		
	
These	 factors	may	help	explain	both	 the	variation	between	EDTA	plasma	and	 (gel)	 serum	as	
reported	 (50)	 and	 the	 differences	 between	 this	 study,	 which	 reports	 that	 ‘serum’	 iPTH	
collected	 in	 gel	 tubes	 in	 unstable	 at	 3h,	 and	 other	 studies	 which	 have	 reported	 that	 iPTH	
collected	into	plain	serum	tubes	is	stable	for	up	to	8	h	(51)	
	
	
2.1.3 Study	3.			
	
In	 this	 study,	 I	 consider	 highly	 sensitive	 C-reactive	 protein	 (hs-CRP)	 sample	 collection	
conditions.	 hs-CRP	 was	 assuming	 increased	 importance	 in	 the	 evaluation	 of	 patients	 with	
coronary	artery	disease	(CAD).		It	is	a	prognostic	indicator	in	acute	coronary	syndromes	(52-54)	
and	 a	 predictor	 of	 future	 coronary	 events	 in	 those	with	 and	without	 overt	 CAD	 (55-56).	 	 As	
small	changes	 in	hs-CRP	concentration	potentially	have	considerable	clinical	 impact,	 I	wished	
to	evaluate	all	aspects	of	the	analytical	process.		
	
Highly	 sensitive	 CRP	 has	 undergone	 numerous	 evaluations	 on	 pre-analytical	 and	 analytical	
variability.		In	healthy	individuals,	hs-CRP	exhibits	no	diurnal	variation	(57),	and	hs-CRP	shows	
little	 variation	 over	 a	 12-month	 period,	 with	 a	 similar	 stability	 of	 measurement	 to	 total	
cholesterol	(58).		Analytical	variability	of	hs-CRP	assays	has	been	assessed	recently	by	Roberts	
and	colleagues,	who	reported	coefficients	of	variation	(CV)	<10%	at	0.15	mg/L	(59).	
	
It	is	widely	recognised	that	sample	collection	tube	type	may	affect	analyte	concentrations.		In	
particular,	 ‘gel’	 tube	 effects	 have	 been	 described	 for	 anticonvulsant	 drugs	 (60)	 and	 intact	
parathyroid	 hormone	 (61).	 However,	 the	 effect	 of	 sample	 collection	 tube	 type	 on	 hs-CRP	
concentration	has	not	been	studied.	
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This	study	aims	to	assess	the	stability	of	serum	and	plasma	hs-CRP	in	different	collection	tubes	
over	a	24-hour	period,	using	the	DPC	Immulite	hs	CRP	assay.		
	
2.1.3.1 Methods	
	
Blood	samples	were	collected	from	seven	patients	with	chronic	renal	failure	(on	dialysis)	into	a	
10	mL	plain	glass	tube	(tube	A;	Lip	Z10/GN),	a	2.7	mL	EDTA	tube	(tube	B	[2.7	ml	KE];	Sarstedt	
Monovet,	Germany)	and	a	4.2	mL	gel	tube	(tube	C	[4.2	ml,	Z	GEL];	Sarstedt	Monovet).	
Samples	 were	 transported	 to	 the	 laboratory	 on	 ice	 and	 remained	 unseparated	 at	 room	
temperature	(17-23°C)	until	centrifuged.		At	20	min	(baseline),	1,	2,	4,	8	and	h,	a	1	mL	sample	
was	 taken	 from	 each	 tube	 and	 centrifuged.	 	 The	 resultant	 supernatant	was	 frozen	 at	 -20°C	
until	 analysis,	which	was	 carried	out	 in	 one	batch	using	 a	DPC	 Immulite	high	 sensitivity	 CRP	
assay	 (LKCR,	 Diagnostic	 Products,	 Los	 Angeles;	 intra-assay	 CV	 =	 4.1%),	 immediately	 after	
thawing.	 	 Statistical	 analysis	 was	 by	 repeat	 measures	 ANOVA	 and,	 where	 significant,	 was	
followed	by	Tukey-Kramer	post-test	comparison.		
	
2.1.3.2 Summary	and	significance	
	
Significant	differences	were	observed	 in	 samples	 separated	at	 0.3	h	 (ANOVA	P=0.0192),	 and	
hs-CRP	 values	 were	 significantly	 higher	 (P<0.05)	 in	 gel	 tubes	 than	 in	 plain	 and	 EDTA	 tubes.		
Otherwise,	there	were	no	significant	between-tube	differences	in	hs-CRP	concentration.		
Within	the	tube	type,	there	were	no	significant	differences	in	hs-CRP	concentration	in	samples	
taken	into	plain	tubes	and	EDTA	tubes	over	the	24-h	period.		In	gel	tubes,	however,	there	were	
significant	 differences	 over	 time	 (ANOVA	 P=0.03),	 with	 hs-CRP	 concentration	 significantly	
lower	(P<0.05)	in	the	samples	separated	at	8	and	24	h,	compared	with	that	in	the	basal	sample	
separated	at	0.3	h.		In	gel	tubes,	hs-CRP	concentration	decreased	by	9.7%	over	24	h.	
	
These	results	demonstrate	a	significant	decline	in	hs-CRP	concentration	over	time,	when	blood	
is	collected	 into	a	gel	tube,	and	support	previous	studies	reporting	the	effect	of	gel	tubes	on	
other	analytes	such	as	therapeutic	drugs	(60)	and	intact	parathyroid	hormone	(61).	
	
Several	studies	have	proposed	that	hs-CRP	be	used	as	a	prognostic	indicator	in	acute	coronary	
syndromes	(54-56)	or	a	predictor	of	future	coronary	events	(57-58).		However,	the	significant	
decline	 in	 hs-CRP	 in	 gel	 collection	 tubes	 observed	 over	 24	 h	 in	 this	 study	 could	 lead	 to	 the	
misclassification	of	patients	in	samples	left	unseparated	for	eight	or	more	hours.		This	may	be	
particularly	important	for	samples	collected	in	the	community	for	evaluation	of	CAD	risk.		
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In	conclusion,	results	from	this	study	suggest	that	caution	should	be	exercised	in	interpreting	
hs-CRP	results	when	the	sample	is	collected	into	a	gel	tube,	as	I	report	a	significant	decline	in	
hs-CRP	concentration	over	time.		
	
	
2.1.4 Study	4.				
	
In	 this	 study,	 I	 considered	 the	 stability	 of	 CRP,	 using	 the	 DPC	 Immulite	 high-sensitivity	 CRP	
assay,	in	samples	collected	into	plain	glass	tubes.			
	
2.1.4.1	Materials	and	methods	
EDTA	tubes	gel	tubes	and	separated	at	20	min	(baseline)	and	1h,2h,	8h	and	24h.	
	
2.1.4.2	Results	
In	samples	separated	at	baseline	the	measured	CRP	concentrations	were	significantly	higher	in	
gel	 tubes	 than	 in	 plain	 and	 EDTA	 tubes.	 	 Otherwise,	 there	 were	 no	 significant	 differences	
between	 tube	 CRP	 concentrations	 at	 any	 time	 point.	 	 In	 gel	 tube	 CRP	 concentrations	 were	
significantly	 lower	 at	 8h	 and	 24h	 when	 compared	 with	 the	 sample	 separated	 at	 baseline.		
There	 were	 no	 significant	 differences	 in	 CRP	 concentrations	 in	 samples	 taken	 into	 plain	 or	
EDTA	tubes	over	24h.		
	
2.1.4.3	Summary	and	significance	
	
These	findings	of	higher	baseline	serum	CRP	concentrations	in	gel	tubes	compared	with	plain	
tubes	are	consistent	with	those	of	Chang	et	al	(63).	Additionally,	I	reported	a	significant	decline	
in	 CRP	 concentrations	 in	 gel	 tubes	 by	 8h	 post	 sampling	 (62).	 These	 findings	 of	 discrepant	
results	from	different	collection	tubes	are	similar	to	previous	studies	reporting	the	effect	of	gel	
tubes	on	other	analytes,	including	therapeutic	drugs	(64)	and	intact	parathyroid	hormone	(65).	
Serum	CRP	concentrations	often	in	the	‘conventional’	reference	range,	have	an	important	role	
in	 the	 evaluation	 of	 cardiovascular	 risk	 and	 are	 of	 prognostic	 value	 in	 acute	 coronary	
syndromes	(66).		
	
The	 between-tube	 differences	 are	 more	 likely	 to	 influence	 clinical	 interpretation	 of	 CRP	 at	
lower	 concentrations	 especially	 where	 CRP	 is	 used	 as	 an	 aid	 to	 assess	 cardiovascular	 risk	
evaluation	and	prognosis	of	acute	coronary	syndromes.		
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I	reported	an	intra-assay	coefficient	of	variation	of	3.36%	at	a	CRP	concentration	of	10.7	mg/L	
using	 the	 Immulite	 high-sensitivity	 CRP	 assay.	 	 However,	 there	 is	 an	 additional	 8.8-10.1%	
variation	(according	to	the	sample	tube	type)	and	a	10.7%	decline	in	CRP	concentrations	if	gel	
tubes	are	used	 for	 sample	 collection.	 Such	variability	due	 to	 sample	 tube	 type	could	 lead	 to	
potential	 misclassification	 of	 patients	 under	 evaluation	 for	 cardiovascular	 risk	 and	 acute	
coronary	syndrome.		
	
	
2.1.5 A	summary	of	Project	1	
	
This	project	 considered	 the	 in	 vitro	stability	of	PTH	and	CRP	assays.	The	 study	demonstrates	
the	 importance	 of	 sample	 tube	 type	 and	 time	 to	 separation	 as	 determinants	 of	 sample	
stability.	These	findings	are	of	significance	as	the	correct	and	optimal	pre-analytical	conditions	
minimise	the	(CVa)	ensuring	appropriate	interpretation	of	the	Biological	variation	(CVi).	These	
papers	 have	 been	 cited	 18	 times	 including	 reviews	 on	 sample	 stability,	 appropriate	 testing	
conditions	and	renal	journals	
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2.2 Project	2.	Intra	individual	variation	in	laboratory	analytes	due	to	ethnicity	
	
This	 project	 contained	 three	 studies,	 which	 considered	 the	 intra-individual	 variation	 due	 to	
ethnicity,	 in	analytes	 commonly	used	or	associated	with	 cardiovascular	disease.	 Specifically	 I	
assessed	the	ethnic	variation	in	total	cholesterol	and	HDL,	ethnic	variation	in	CRP	and	maternal	
variation	of	B12	in	white	Caucasians	living	in	the	UK.	This	 is	an	important	area	of	research	as	
the	incidence	of	cardiovascular	disease	is	observed	to	be	higher	in	some	ethnic	populations,	I	
assessed	whether	some	of	the	variation	in	analyte	results	was	due	to	ethnic	variation	and	thus	
could	determine	the	non-pathophysiological	component	of	the	total	variation.		
	
2.2.1 Study	1		
	
For	this	study,	I	investigated	the	ethnic	differences	in	total	and	HDL	cholesterol	concentrations	
between	Caucasians	and	predominately	Punjab	Sikh	 Indo-Asians.	This	 is	as	there	 is	 increased	
prevalence	of	coronary	heart	disease	(CHD),	in	Indo-Asians	resident	in	the	UK	is	unexplained	by	
differences	in	cardiovascular	risk	factors	of	hypercholesterolaemia,	hypertension,	smoking	or	a	
family	history	of	CHD	 (67-68).	Although	diabetes	mellitus	 is	more	 common	 in	 Indo-Asians,	 it	
does	not	fully	explain	the	increased	prevalence	of	CHD.		
	
Low	 serum	 HDL	 cholesterol	 (HDLC)	 concentrations,	 widely	 reported	 in	 Indo-Asians,	 may	
contribute	 to	 the	 increased	 prevalence	 of	 CHD	 amongst	 this	 group.	 However,	 it	 has	 been	
suggested	 that	 there	 may	 be	 a	 difference	 in	 cardiovascular	 risk	 factors	 between	 culturally	
different	Indo-Asian	groups	(69).	I	therefore	compared	serum	total	cholesterol	(TC)	and	HDLC	
in	Indio-Asian	and	Caucasian	subjects	residing	in	Wolverhampton,	UK,	for	whom	a	laboratory	
CHD	risk	assessment	had	been	requested.	
	
2.2.1.1 Subjects	and	methods	
	
General	 practitioners	 (GPs)	 were	 provided	 with	 a	 laboratory-based	 10	 year	 CHD	 risk	 score	
calculation	based	on	the	Framingham	equation	(59).	This	calculation	uses	the	individual’s	age,	
sex,	systolic	blood	pressure	(BP),	TC	concentration,	HDLC	concentration,	and	the	presence	or	
absence	 of	 smoking,	 diabetes	mellitus	 and	 left	 ventricular	 hypertrophy.	 Clinical	 information	
was	 collected	 from	 a	 sticker	 fixed	 on	 the	 pathology	 request	 form,	 Afro/Caribbean,	 Asian,	
Chinese	 and	 ‘other’).	 Patients	 were	 selected	 at	 the	 discretion	 of	 their	 GPs.	 	 Since	 most	
laboratory	CHD	risk	assessment	requests	 in	 Indo-Asians	were	on	subjects	aged	40-60	years,	 I	
restricted	the	study	to	this	age	group.	 	Other	exclusion	criteria	 included	overt	macrovascular	
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disease	 and	 lipid-lowering	 medication.	 Serum	 TC	 and	 HDLC	 concentrations	 were	 measured	
automatically	 (DiaSys	 Diagnostic	 Systems	 Gmbh	 &	 Co,	 Holzheim,	 Germany	 and	 Bio-Stat	
Diagnostic	 Systems,	 Stockport,	 UK,	 respectively).	 	 Inter-assay	 and	 intra-assay	 coefficients	 of	
variation	for	TC	were	respectively	1.22%	and	0.61%	and	for	HDLC	were	respectively	1.93%	and	
0.75%.	
	
Data	 were	 non-parametric.	 	 The	 Mann-Whitney	 U-test	 was	 therefore	 used	 to	 assess	 the	
differences	between	Indo-Asians	and	Caucasians.		The	Kruskal-Wallis	test	with	Dunn	post-test	
comparison	 was	 the	 used	 to	 assess	 the	 differences	 between	 ethnic	 male	 and	 female	
subgroups.		Results	are	expressed	as	medians	with	95%	confidence	intervals	in	parentheses.		
	
2.2.1.2 Results	
	
Complete	 demographic,	 clinical	 and	 biochemical	 data	 sets	 were	 collected	 in	 94	 Indo-Asian	
women.		129	Indo-Asian	men,	366	Caucasian	women	and	421	Caucasian	men.		Table	2.2	shows	
serum	TC	concentration	was	similar	in	Caucasians	and	Indo-Asians	but	Indo-Asians	had	a	lower	
average	HDLC	concentration	(P<0.001)	and	therefore	a	higher	TC:HDLC	ratio	(P<0.005).		
	
	 Caucasian	 Indo-Asian	 P	value	
n	 787	 223	 	
Age	(years)	 52	(51.2-52.0)	 49(48.9-50-5)	 <0.0001	
Diabetics	(%)	 16.9	 24.8	 0.3055	
Current	smokers	(%)	 40.7	 12-2	 <0.0001	
Total	cholesterol	(mmol/L)	 5.8	(5.7-5-9)	 5.7	(5.6-5.9)	 0.0769	
HDL	cholesterol	(mmol/L)	 1.4	(1.3-1.4)	 1.3	(1.2-1.3)	 <0.0001	
Total:HDL	cholesterol		ratio	 4.6	(4.5-4.7)	 4.8	(4.6-5.0)	 0.004	
Systolic	BP	(mmHg)	 140	(139-142)	 136	(133-138)	 	
10-year	CHD	risk	(%)	 10.6	(10.1-11-2)	 9.4	(8.6-10.2)	 0.0714	
	
Table	2.2	Cardiovascular	risk	factors	in	Indo-Asian	and	Caucasian	subjects.	Results	are	medians	
(95%	confidence	intervals)	
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Men	and	women	in	the	two	ethnic	groups	had	similar	TC	concentrations.		Indo-Asian	women,	
Indo-Asian	 men	 and	 Caucasian	 men	 had	 similar	 HDLC	 concentrations	 but	 these	 were	 on	
average	 lower	 (P<0.001)	 than	 those	 in	 Caucasian	 women.	 	 The	 TC:LHDLC	 ratio	 was	 similar	
within	each	gender	group.		Indo-Asian	and	Caucasian	men	had	a	higher	TC:HDLC	ratio	than	did	
Caucasian	women	(P<0.001)	but	a	similar	TC:HDLC	ratio	compared	to	Indo-Asian	women.		
	
2.2.1.3 Summary	and	significance		
	
I	found	that	TC	concentration	in	Indo-Asians	and	Caucasians	was	similar	and	this	is	consistent	
with	 previous	 studies	 (67).	 The	 lower	 HDLC	 concentration	 found	 in	 Indo-Asians	 when	
compared	with	Caucasians	was	consistent	with	previous	studies	(68-69).		I	suggest	this	is	due	
to	higher	HDLC	concentrations	in	Caucasian	women,	since	HDLC	concentrations	were	similar	in	
Indo-Asian	women,	Indo-Asian	men	and	Caucasian	men.		
	
Previous	studies	have	found	higher	HDLC	concentrations	in	Caucasian	and	Indo-Asian	women	
compared	with	men	 (70-71).	The	absence	of	a	sex	difference	 in	HDLC	concentration	 in	 Indo-
Asians	 in	 this	 study,	 however,	 has	 been	 previously	 reported	 in	 some	 indigenous	 Indian	
communities	 (72)	but	 this	 finding	 remains	unexplained.	 	 In	women,	 the	 lower	average	HDLC	
concentration	 in	 Indo-Asian	men	 and	 Caucasian	men	 had	 similar	 HDLC	 concentrations.	 	 The	
lower	 HDLC	 concentration.	 	 The	 lower	 HDLC	 concentrations	 in	 Indo-Asian	 women	 may	 be	
related	to	lifestyle	(for	example,	exercise,	menopausal	status	and	alcohol	intake)	or	medication	
(e.g.	 oral	 contraceptives	 pill	 or	 hormone	 replacement	 therapy),	 both	 of	 which	 affect	 HDLC	
concentrations.		It	is	also	possible	that	the	higher	than	‘expected’	HDLC	in	Indo-Asian	men	may	
be	likewise	influenced	by	lifestyle	factors.		
	
It	has	been	reported	that	there	may	be	a	variation	of	CHD	risk	factors	within	culturally	diverse	
Indo-Asians	 (68).	 In	 this	 study	 the	 Indo-Asian	 subjects	 were	 predominately	 Punjabi	 Sikhs,	
whereas	other	studies	have	often	included	culturally	diverse	Indo-Asian	groups.		The	results	in	
this	study	are	consistent	with	a	previous	study	which	observed	similar	HDLC	concentrations	in	
Sikh	 Indo-Asian	men	and	Caucasian	men	but	 lower	HDL	concentrations	 in	Muslim	and	Hindu	
Indo-Asian	men	(73,	supporting	the	notion	of	diversity	of	CHD	risk	factors	amongst	Indo-Asians	
(68).	
	
HDLC	concentrations	are	 lower	 in	 Indo-Asian	women	that	 in	Caucasian	women	but	similar	 in	
Indo-Asian	men	and	Caucasian	men.	 	This	difference	is	 likely	to	be	social	or	environmental	 in	
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origin.		In	developing	strategies	to	prevent	CHD	in	South	Asians	consideration	should	be	given	
to	possible	diversity	of	CHD	risk	factors	between	culturally	different	Indo-Asian	groups.		
	
	
2.2.2 Study	2	
	
This	considered	the	ethnic	variation	 in	C-reactive	protein:	UK	resident	 Indo-Asians	compared	
with	 Caucasians.	 The	 increased	 prevalence	 of	 coronary	 heart	 disease	 (CHD)	 in	 UK	 resident	
Indo-Asians	 is	 unexplained	 by	 the	 traditional	 cardiovascular	 risk	 factors	 of	 dyslipidaemia,	
hypertension,	 smoking	 and	 diabetes	 mellitus	 (74-76).	 C-reactive	 protein	 (CRP)	 has	 been	
implicated	 in	 the	 pathogenesis	 of	 CHD	but	 the	 data	 on	 ethnic	 variation	 in	 CRP	 is	 conflicting	
(77).	I	therefore	investigated	whether	CRP	could	help	explain	the	increased	prevalence	of	CHD	
in	 Indo-Asians.	For	 this	 study	 I	measured	CRP,	using	a	highly	 sensitive	assay,	 in	102	men	 (63	
Caucasians	 and	 39	 Indo-Asians)	 and	 89	 women	 (58	 Caucasians	 and	 31	 Indo-Asians).	 All	
subjects,	aged	between	40	and	70	years,	were	nondiabetic	and	non-smokers.	
	
2.2.2.1 Results	
	
Serum	 CRP	 correlated	 (P	 <	 0.05)	 positively	 with	 coronary	 risk.	 Serum	 HDL	 cholesterol	
concentrations	 were	 lower	 (P<0.05)	 in	 Indo-Asian	 women	 when	 compared	 with	 Caucasian	
women,	 but	 otherwise	 the	 ethnic	 groups	 were	 matched	 for	 calculated	 coronary	 risk	 and	
cardiovascular	risk	factors.	Serum	CRP	concentrations	were	similar	in	Indo-Asians	(women	2.29	
(1.52)	mg/l	[mean	(SD)];	men	1.77	(1.46)	mg/l)	and	Caucasians	(women	2.23	(1.54)	mg/l;	men	
1.94	(1.45)	mg/l).	
	
2.2.2.2 Summary	and	significance	
	
This	 work	 showed	 that	 altered	 CRP	 concentrations	 do	 not	 appear	 to	 be	 implicated	 in	 the	
increased	prevalence	of	CHD	in	UK	resident	Indo-Asians.	
	
	
2.2.3 Study	3		
	
In	 this	 study,	 I	 investigated	 the	 relationship	 between	 low	maternal	 vitamin	 B12	 status	 and	
lower	 cord	 blood	 HDL	 cholesterol	 in	 white	 Caucasians	 living	 in	 the	 UK.	 Previous	 studies	 in	
South	Asian	population	show	that	low	maternal	vitamin	B12	associates	with	insulin	resistance	
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and	 small	 for	 gestational	 age	 in	 the	 offspring	 (78).	 Low	 vitamin	 B12	 status	 is	 attributed	 to	
vegetarianism	in	these	populations	(79).	It	is	not	known	whether	low	B12	status	is	associated	
with	metabolic	 risk	 of	 the	 offspring	 in	whites,	where	 the	 childhood	metabolic	 disorders	 are	
increasing	rapidly	 (80).	Here,	 I	studied	whether	maternal	B12	 levels	associate	with	metabolic	
risk	of	the	offspring	at	birth.	
	
2.2.3.1 Methods		
	
This	was	a	cross-sectional	study	of	91	mother-infant	pairs	(n	=	182),	of	white	Caucasian	origin	
living	 in	 the	UK.	 Blood	 samples	were	 collected	 from	white	 pregnant	women	 at	 delivery	 and	
their	newborns	(cord	blood).	Serum	vitamin	B12,	folate,	homocysteine	as	well	as	the	relevant	
metabolic	risk	factors	were	measured.	
	
2.2.3.2 Results		
	
The	 prevalence	 of	 low	 serum	 vitamin	 B12	 (<191	 ng/L)	 and	 folate	 (<4.6	 μg/L)	were	 40%	 and	
11%,	respectively.	Maternal	B12	was	inversely	associated	with	offspring's	Homeostasis	Model	
Assessment	 2-Insulin	 Resistance	 (HOMA-IR),	 triglycerides,	 homocysteine	 and	 positively	 with	
HDL-cholesterol	after	adjusting	for	age	and	BMI.	In	regression	analysis,	after	adjusting	for	likely	
confounders,	 maternal	 B12	 is	 independently	 associated	 with	 neonatal	 HDL-cholesterol	 and	
homocysteine	but	not	triglycerides	or	HOMA-IR.	
	
2.2.3.3 Summary	and	conclusions	
	
Our	 study	 shows	 that	 low	 B12	 status	 is	 common	 in	 white	 women	 and	 is	 independently	
associated	with	adverse	cord	blood	cholesterol.	
	
2.2.4 A	summary	of	Project	2		
	
This	project	studied	the	intra	individual	variation	in	laboratory	analytes	due	to	ethnicity.	Often	
reference	 ranges	are	not	 specific	 for	ethnic	 variation	and	 therefore	when	clinically	 assessing	
the	 test	 results	 one	 might	 overlook	 the	 natural	 variation	 that	 may	 occur	 due	 to	 ethic	
differences	in	the	patient	population.		
	
Data	 presented	 in	 the	 studies	 demonstrates	 significant	 differences	 in	 result	 results	 between	
different	 ethnicities	 and	 therefore	 highlights	 the	 need	 for	 greater	 awareness	 of	 those	
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differences	when	 interpreting	 clinical	 biochemistry	 results.	 These	papers	have	been	 cited	53	
times	and	through	those	citations	have	increased	awareness	of	the	significance	of	ethnic	origin	
as	a	source	of	variability	in	laboratory	results.	More	specifically	the	citations	include	reviews	on	
insulin	 resistance,	 glycated	haemoglobin	and	 renal	 function	and	papers	describing	 the	wider	
impact	on,	for	example,	other	ethnic	minorities	such	as	aboriginal	Australians.		
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2.3 Project	 3.	 Variation	 in	 laboratory	 results	 due	 to	 pre-existing	 conditions	
causing	an	elevation	in	interferants	that	affect	common	laboratory	tests.	
	
Many	 conditions	 will	 have	 an	 effect	 on	 the	metabolism	 of	 many	 common	 laboratory	 tests.	
Some	of	those	changes	may	be	have	appropriate	sensitivity	and	specificity	to	be	markers	 for	
the	 disease,	 others	 analytes	 will	 not	 and	 are	 seen	 as	 consequential	 observations.	 However	
significant	rises	in	some	analytes	(as	a	non-specific	consequence	of	the	original	condition)	can	
cause	an	interference	in	the	testing	of	others.	This	will	cause	a	variation	in	results.	My	work	in	
this		area	has	investigated	whether	there	is	a	significant	effect	of	lipaemia	on	other	commonly	
requested	tests	as	this	 is	often	quoted	as	a	reason	for	the	not	being	able	to	issue	a	result.	 In	
addition	I	studied	whether	the	observation	of	a	raised		prolactin	seen	in	rheumatoid	arthritis,	is	
genuine	or	 laboratory	artefact.	Finally,	a	series	of	case	 investigations	 into	the	often	reported	
pseudo-pseudo	hypercalcaemia		in	Waldenstroms	macroglobulinaemia,	and	whether	this	was	
due	to	an	interference	in	the	calcium	method	by	the	high	protein	concentrations	observed	in	
that	condition.	
	
2.3.1 Study	1	
	
This	 investigation	was	to	quantify	the	effect	that	 interference	from	lipaemia	has	on	common	
laboratory	 tests.	 Lipaemia	 is	 reported	 to	 interfere	 in	 many	 routine	 assays.	 Many	 reagent	
suppliers	provide	information	on	the	effect	of	lipaemia	in	their	assays,	but	this	is	often	vague,	
not	 quantified	 and	 may	 not	 be	 instrument-specific	 (81-82).	 Lipaemia,	 like	 haemolysis	 and	
icterus,	 causes	 chromophoric	 interference	 in	 photometric	 analyses	 due	 to	 high	 background	
readings,	 interference	 at	 the	 measured	 wavelength	 and	 light	 scattering	 caused	 by	 the	
interfering	substance	(82-83).	The	interference	may	be	dose-dependent	for	some	analytes	but	
not	 for	 all	 (82).	 The	 interference	 from	 lipaemia	 can	 be	 minimised	 in	 a	 number	 of	 ways,	
including	the	use	of	a	sample	blank	reading,	kinetic	analysis,	changing	the	wavelength	at	which	
the	reaction	is	read	to	one	at	which	there	is	minimal	absorbance	from	the	interferant	(84-85),	
and	the	use	of	commercial	preparations	that	clear	the	lipid	content	from	serum	(86).	
	
In	 the	 laboratory	 setting,	 staff	 use	 different	 methods	 –	 such	 as	 visual	 inspection,	 lipaemia	
index,	 serum	 indices	 and	 triglyceride	 concentration	 –	 to	 determine	 the	 degree	 of	 turbidity	
from	lipaemia.	These	assessments,	however,	may	be	inaccurate	as	the	degree	of	interference	
from	lipaemia	is	method-	and	instrument-dependent	(81-82).	In	this	study,	I	aimed	to	evaluate	
the	 effects	 of	 lipaemia	 and	 LipoClear,	 a	 non-toxic	 polymer	 for	 serum	 lipid	 clearance,	 on	 14	
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tests	commonly	analysed	on	the	Bayer	Opera	analyser,	prior	 to	 the	 introduction	of	Lipoclear	
into	our	routine	laboratory	repertoire.	
	
2.3.1.1 Materials	and	methods	
	
A	 total	of	14	analytes	were	measured	 in	up	 to	44	 serum	samples	with	either	no	 lipaemia	or	
varying	 degrees	 of	 lipaemia	 (mean	 serum	 triglyceride	 6.89	 (range	 0.58–284)	 mmol/L)	 using	
methods	recommended	for	use	by	the	 instrument	manufacturer.	Twelve	samples	had	serum	
triglyceride	 <2	 mmol/L;	 20	 samples	 had	 a	 serum	 triglyceride	 >2	 and	 <10	 mmol/L,	 and	 12	
samples	had	a	serum	triglyceride	>10	mmol/L.	Each	analyte	was	determined	before	and	after	
treatment	 with	 Lipoclear	 (Phisec	 International,	 UK)	 on	 a	 Bayer	 Opera	 analyser	 (Bayer	 AG,	
Germany).	A	0.5	mL	serum	sample	was	added	to	0,1	mL	LipoClear,	mixed	and	left	to	stand	for	5	
min.	 The	mixture	was	 centrifuged	and	 the	 supernatant	 analysed.	Results	were	multiplied	by	
1.2	 to	 correct	 for	 the	 initial	 dilution.	 Significance	 differences	 before	 and	 after	 the	 use	 of	
LipoClear	were	calculated	using	the	paired	t-test	and	Wilcoxon	matched	pairs	 for	parametric	
and	non-parametric	data.	
	
2.3.1.2 Results	
	
Table	 2.3	 shows	 that	 with	 the	 exception	 of	 alanine	 transaminase	 (ALT),	 amylase	 and	
bicarbonate,	significant	differences	in	the	other	analyte	values	before	and	after	treatment	with	
Lipoclear	were	seen	using	standard	statistical	 techniques.	When	analytical	CV	was	taken	 into	
account,	 only	 phosphate,	 total	 protein,	 cholesterol	 and	 triglyceride	 showed	 significant	
analytical	change.	
	
Analyte	 Analytical	CV	
2.8x	
CV	 %	Difference	 Significance	
Urea	 2.5	 7.0	 +4.4	 Not	significant	
Creatinine	 2.6	 7.3	 +2.1	 Not	significant	
Albumin	 1.3	 3.6	 -2.4	 Not	significant	
Alkaline	
Phosphatase	 4.9	 13.7	 -1.0	 Not	significant	
Alanine	
Transaminase	 3.0	 8.4	 0	 Not	significant	
Amylase	 3.5	 9.8	 0	 Not	significant	
Phosphate	 1.6	 4.5	 -9.5	 Significant	
Glucose	 2.6	 7.3	 +3.3	 Not	significant	
Bicarbonate	 4.6	 12.9	 +4.8	 Not	significant	
Total	protein	 2.3	 5.6	 -14.5	 Significant	
Total	bilirubin	 3.7	 10.4	 +4.5	 Not	significant	
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Calcium	 2.1	 5.9	 -3.9	 Not	significant	
Triglyceride	 1.2	 3.4	 -74	 Significant	
Cholesterol	 2.5	 7.0	 -54	 Significant	
	
Table	 2.3	 Comparison	of	 analyte	 coefficients	 of	 variation	with	%	difference	 in	 analyte	 result	
before	and	after	lipid	extraction		
	
2.3.1.3 Summary	and	significance	
	
This	study	showed	that	most	methodologies	used	on	the	Bayer	Opera	appeared	to	be	subject	
to	 statistically	 significant	 interference	 from	 lipaemia	 when	 evaluated	 by	 standard	 statistical	
methods,	but	these	do	not	consider	the	analytical	 imprecision	of	assays.	When	the	analytical	
CV	was	taken	into	account,	most	of	the	differences	failed	to	achieve	critical	significance.	Only	
phosphate,	 protein,	 cholesterol	 and	 triglyceride	 values	 remained	 critically	 different	 after	 the	
addition	of	LipoClear.	
	
These	 findings	 support	 a	 previous	 study	of	 LipoClear	 (86)	 and	were	expected	as	 Lipoclear,	 a	
non-ionic	 polymer,	 precipitates	 lipoproteins	 and	 phospholipids.	 Lipaemia	 did	 not	 critically	
affect	measurement	of	other	analytes,	probably	because	the	Bayer	Opera	performs	an	 initial	
blank	reading	at	the	start	of	the	reaction,	supporting	previous	reports	recommending	the	use	
of	 serum	 blanks	 in	 minimising	 lipaemic	 interference	 (81-82).	 However,	 these	 results	 are	 at	
variance	 with	 the	manufacturer's	method	 sheets,	 which	 indicate	 lipaemia	 interference	 with	
ALT,	amylase,	glucose,	bicarbonate	and	calcium	methods.	
	
I	 concluded,	 LipoClear	 does	 reduce	 lipaemia	 but	 most	 methodologies	 are	 often	 sufficiently	
robust	 to	 avoid	 interference	 from	 lipaemia.	 Therefore,	 I	 recommend	 that	 individual	
laboratories	quantify	interference	from	lipaemia	w	for	their	specific	methods	and	instruments,	
as	 the	 interference	 could	 be	 analyser-	 and/or	 reagent-specific.	 Only	 if	 there	 is	 significant	
interference	should	the	use	of	lipid	clearing	agents	be	considered.		
	
	
2.3.2 Study	2		
	
It	has	been	suggested	that	prolactin	may	have	a	pathogenic	role	in	rheumatoid	arthritis	(RA),	
since	 in	 vitro	 studies	 have	 shown	 that	 prolactin	 enhances	 inflammatory	 responses	 (87-88).	
Indeed,	increased	serum	prolactin	concentrations	have	been	reported	in	patients	with	RA	(89-
90).	Furthermore,	dopamine	agonists,	which	suppress	pituitary	secretion	of	prolactin,	may	be	a	
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useful	 adjunct	 to	 treatment	 in	 patients	with	RA	 (91).	 Prolactin	 circulates	 in	 several	 different	
molecular	 forms,	predominantly	monomeric	prolactin	but	also	as	small	but	variable	amounts	
of	 big	 prolactin	 and	 "big,	 big	 prolactin'	 (macroprolactin).	 The	 binding	 of	 prolactin	 to	 an	
immunoglobulin	 forms	macroprolactin.	Since	macroprolactin	 is	 less	physiologically	active	and	
is	 less	 effectively	 cleared	 than	 free	 unbound	 prolactin,	 the	 total	 concentration	 of	 serum	
prolactin	increases.	Depending	on	the	immunoassay	used,	macroprolactin	may	account	for	4-
5%	of	cases	of	hyperprolactinaemia	(92)	and	has	also	been	reported	 in	normoprolactinaemic	
samples	(93).	
	
Systemic	lupus	erythematosus	(SLE),	an	autoimmune	disease	with	an	increased	prevalence	of	
serum	autoantibodies,	is	associated	with	macroprolactinaemia	(94).	RA	is	also	associated	with	
an	 increased	 frequency	 of	 circulating	 antibodies	 and	 macroprolactin	 has	 been	 reported	 in	
patients	 with	 RA	 (95-96).	 It	 is	 therefore	 possible	 that	macroprolactin	 could	 account	 for	 the	
hyperprolactinaemia	observed	in	RA.	
	
2.3.2.1 Material	and	methods	
	
Sixty	women	with	RA	and	31	women	with	osteoarthritis,	who	served	as	controls,	were	studied.	
A	blood	sample	for	serum	prolactin	was	collected	at	least	2h	after	awakening,	between	09.30	
and	12.00h.	Polyethylene	glycol	 (PEG)	was	used	 to	precipitate	and	 remove	big	prolactin	and	
macroprolactin	 from	 serum	 samples.	 Serum	 prolactin	was	 therefore	measured	 before	 (total	
prolactin)	 and	after	 (free	or	monomeric	prolactin)	precipitation	with	PEG	6000	 (97-98)	using	
the	Architect	prolactin	assay	(Abbott	Laboratories,	Diagnostics	Division,	IL,	USA).		
	
2.3.2.2 Statistical	analysis	
	
Data	were	normally	distributed.	Unpaired	and	paired	Student's	t	tests	were	therefore	used	to	
assess	 differences	 in	 variables	 between	 groups	 and	 within	 groups	 respectively.	 Results	 are	
expressed	as	mean	(S.D).	Pearson’s	linear	correlation	was	used	to	measure	the	significance	of	
association	between	variables.		
	
	 RA	 Controls	 P	
Number	of	subjects	 60	 31	 	
Age	(yr)	 56.7	(12.9)	 53.1	(16.1)	 0.287	
ESR	(mm/hr)	 27.7	 -	 -	
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Total	prolactin	(mU/l)	 225.6	(104.6)	 175.0	(68.5)	 0.0387	
Free	prolactin	(mU/l)	 201.6	(95.4)	 154.0	(60.9)	 0.0127	
	
Table	2.4	 	Clinical	and	biomedical	results	of	women	with	RA	arthritis	and	their	controls.	Data	
are	mean	(S.D).	
	
2.3.2.3 Results		
	
Demographic,	 clinical	 and	 biochemical	 data	 are	 shown	 in	 Table	 2.4.	 No	 subjects	 had	
hyperprolactinaemia	 or	 macroprolactinaemia.	 Serum	 concentrations	 of	 total	 and	 free	
(monomeric)	prolactin	were	higher	(P<0.05)	in	women	with	RA	(225.6	(104.6)	and	201.6	(95.4)	
mu/l	 respectively	 than	 in	 controls	 175.0	 (68.5)	 and	154.0	 (60.9)	mU/	 respectively).	Although	
serum	 prolactin	 fell	 following	 precipitation	 in	 women	 with	 RA	 and	 controls,	 this	 was	 not	
significant	 (P=0.1936	 and	 P	 =	 0.2877	 respectively).	 In	 women	 with	 RA,	 there	 were	 no	
correlations	 between	 ESR	 and	 total	 prolactin	 (r=	 0.1163;	 P	 =	 0.3762)	 or	 free	 prolactin	
(r=0.07725;	P	=	0.5574),	but	ESR	inversely	correlated	with	the	percentage	of	free	prolactin	of	
the	total	prolactin	(r=-0.3278;	P=0.01.06).		
	
2.3.2.4 Summary	and	significance		
	
Although	 no	 subjects	 in	 this	 study	 had	 hyperprolactinaemia,	 I	 report	 higher	 serum	prolactin	
concentrations	in	women	with	RA	compared	with	controls.	This	result	is	consistent	with	other	
studies	 similarly	 reporting	 higher	 total	 prolactin	 concentrations	 in	 patients	 with	 RA	 than	 in	
controls,	but	differs	from	studies	reporting	similar	or	lower	prolactin	concentrations	in	patients	
with	RA.	In	addition,	I	report	for	the	first	time	higher	free	prolactin	concentrations	in	subjects	
with	 RA.	 It	 is	 therefore	 unlikely	 that	 the	 different	 total	 prolactin	 concentrations	 reported	 in	
various	studies	are	solely	due	to	varying	macroprolactin	cross-	reactivity	in	different	prolactin	
assays.		
	
Prolactin	 has	 a	 role	 in	 immunomodulation	 and	 it	 has	 been	 proposed	 that	 prolactin	 is	 a	 risk	
factor	 for	 the	 development	 of	 autoimmunity	 (95).	However,	 it	 remains	 unclear	whether	 the	
higher	prolactin	concentrations	are	the	cause	or	consequence	of	RA.		
I	 confirmed	higher	 free	prolactin	 concentrations	 in	 subjects	with	RA.	 I	 found	no	evidence	 to	
support	 the	 notion	 that	 low	 biological	 activity	 macroprolactin	 contributes	 to	 the	 elevated	
prolactin	concentrations	observed	in	RA.	
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2.3.3 Study	3	
	
This	 was	 a	 case	 report	 on	 Pseudo-pseudohypercalcaemia	 and	 apparent	 primary	
hyperparathyroidism	in	Waldenström's	macroglobulinaemia,	which	is	a	malignant	disorder	of	B	
lymphocytes	 characterised	 by	 high	 serum	 concentrations	 of	 monoclonal	 IgM,	 a	
lymphoplasmacytic	 infiltrate	 of	 the	 bone	 marrow	 and	 an	 elevated	 serum	 viscosity.	 (99)	
Hypercalcaemia	 is	 unusual	 in	 Waldenström's	 macroglobulinaemia	 (100)	 but	 a	 characteristic	
feature	 of	 primary	 hyperparathyroidism.	 Although	 Waldenström's	 macroglobulinaemia	 is	
uncommon,	primary	hyperparathyroidism	 is	 relatively	common.	 It	 is,	 therefore,	possible	 that	
the	 two	 conditions	may	 coexist.	 I	 describe	 a	 case	 of	 apparent	 primary	 hyperparathyroidism	
due	to	pseudo-pseudohypercalcaemia	in	association	with	Waldenström's	macroglobulinaemia.	
	
2.3.3.1 Case	report	
	
A	 74-year-old	 man	 was	 diagnosed	 with	 Waldenström's	 macroglobulinaemia	 when	 he	
presented	in	May	2002	with	lethargy,	weight	loss	and	nasal	bleeds,	and	an	IgM	K	paraprotein	
of	 31.5	 g/l	 (IgM	 reference	 range:	 0.5–2	 g/l).	 He	 received	 chemotherapy	 courses	 and	 in	
February	 2003	 was	 referred	 to	 the	 urologists	 with	 prostatism.	 His	 rectal	 examination	 was	
normal;	however,	his	 serum	prostate-specific	antigen	 (PSA)	was	 raised	 (reference	 range	0.1–
6.5	g/1;	age	270	years).	A	four-quadrant	prostatic	biopsy	followed,	but	did	not	show	malignant	
infiltration	 of	 the	 prostate.	 At	 an	 oncology	 review	 in	 April	 2003,	 it	was	 noticed	 that	 he	 had	
asymptomatic	 hypercalcaemia	 (serum	 adjusted	 calcium	 level	 2.86	 mmol/l,	 reference	 range	
2.17-2.66	mmol/l,	Arsenazo	III	dye	binding	method).	A	persistently	elevated	serum	PSA	of	52.2	
g/l	measured	in	May	2003	had	instigated	a	second	four-quadrant	prostatic	biopsy,	which	was	
inconclusive	of	a	diagnosis	of	prostatic	carcinoma.	Serum	calcium	levels	remained	elevated	at	
2.89	 mmol/l.	 The	 possibility	 of	 hypercalcaemia	 due	 to	 metastatic	 bone	 disease,	 although	
uncommon	in	patients	with	prostate	cancer	despite	the	high	frequency	of	skeletal	metastases,	
prompted	 an	 isotope	 bone	 scan;	 however,	 it	 did	 not	 show	 any	 metastatic	 lesions.	 The	
diagnosis	of	primary	hyperparathyroidism	was	then	considered	on	the	basis	of	the	presence	of	
a	consistently	elevated	serum	adjusted	calcium	level	of	3.03	mmol/l	with	inappropriately	non-
suppressed	two	serum	parathyroid	hormone	results	(4	and	44	pmol/l;	reference	range	1.6-6.9	
pmol/l,	 DPC	 immulite)	 and	 a	 normal	 serum	 creatinine	 level	 of	 94	 umol/l.	 Subsequently,	 an	
ultrasound	 of	 the	 neck	 was	 performed,	 which	 suggested	 the	 presence	 of	 a	 parathyroid	
adenoma	 in	 the	 posterior	 inferior	 part	 of	 the	 left	 thyroid	 lobe.	 However,	 in	 July	 2003,	 on	
metabolic	 review,	 the	 presence	 of	 a	 normal	 serum	 ionised	 calcium	 level	 of	 1.10	 mmol/l	
(reference	 range	 1.11-1.3	mmol/l	measured	 on	 a	 Radiometer	 ABL700)	 and	 a	 normal	 fasting	
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urine	 calcium	 excretion	 of	 0.01.2	 mmol/l	 GF	 (reference	 range	 Cae	 <0.045	 mmol/l	 GF)	 has	
excluded	 genuine	 hypercalcaemia	 despite	 the	 repeatedly	 elevated	 serum	 adjusted	 Calcium	
level	of	3.1	mmol/l.	
	
The	 diagnosis	 of	 pseudo	 hypercalcaemia	 was	 made	 and	 was	 postulated	 to	 be	 due	 to	 an	
abnormal	 binding	 of	 calcium	 molecules	 to	 the	 IgM	 paraprotein	 (100).	 This	 was,	 however,	
excluded	when	gel	filtration	chromatography	showed	a	similar	pattern	between	the	patient's	
sample	and	that	of	a	normal	control.	Both	samples	showed	two	peaks	of	calcium:	the	first	peak	
associated	with	albumin	and	the	second	peak	represented	the	complexed	calcium;	however,	
none	was	associated	with	the	 IgM	paraprotein	3,	 thus	excluding	calcium-paraprotein	binding	
as	 a	 cause	 of	 the	 falsely	 elevated	 serum	 calcium	 levels.	 Additional	 investigation	 with	
measurement	of	 serum	calcium	 level	on	 the	 same	patient's	 sample	 (serum	adjusted	calcium	
level	of	3.1	mmol/l)	with	the	o-cresolphthalein	complexone	(CPC)	method	gave	a	calcium	level	
of	 2.19	 mmol/l	 (reference	 range	 2.1-2.55	 mmol/l),	 and	 with	 atomic	 absorption	
spectrophotometry	gave	a	calcium	 level	of	2,4	mmol/l	 (reference	 range	2,2-	2.6	mmol/l).	All	
these	findings	led	to	the	conclusion	of	interference	of	the	IgM	paraprotein	with	the	Arsenazo	
III	dye	binding	calcium	method.4	
	
In	November	2003,	histological	examination	of	repeat	four	quadrant	prostatic	biopsies	 in	the	
presence	of	 a	PSA	of	79	g/1	 (reference	 range	0.1–6.5	g/l,	 age	270	years)	had	 confirmed	 the	
diagnosis	of	an	adenocarcinoma	for	which	he	is	currently	receiving	treatment.	
	
2.3.3.2 Summary	and	significance	
	
The	 presence	 of	 pseudo-pseudo-hypercalcaemia	 in	 association	 with	 Waldenström's	
macroglobulinaemia	 had	 resulted	 in	 an	 erroneous	 provisional	 diagnosis	 of	 primary	
hyperparathyroidism.	 In	 patients	 with	 Waldenström's	 macroglobulinaemia,	 genuine	
hypercalcaemia	 is	 rare	 (99-100)	 and	pseudo-hypercalcaemia	 is	 even	 rarer	 (101-102).	 Indeed,	
there	 were	 only	 two	 case	 reports	 of	 pseudo-hypercalcaemia	 in	 Waldenström's	
macroglobulinaemia	 due	 to	 either	 calcium	 binding	 to	 the	 IgM	 paraprotein	 or	 paraprotein	
interference	 in	 the	 calcium	Arsenazo	 III	method.	 The	 findings	 for	 this	 patient	 are	 consistent	
with	the	notion	of	IgM	paraprotein	interference	with	the	calcium	Arsenazo	III	method	and	the	
consequent	pseudo-pseudo-hypercalcaemia.	The	mechanism	of	the	interference	is	likely	to	be	
increased	turbidity	produced	by	paraprotein	interaction	with	the	acidic	medium	of	the	calcium	
Arsenazo	III	reagent	and	not	with	the	alkaline	CPC	method	(101).	
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It	 is	 important	to	 identify	patients	with	falsely	elevated	serum	calcium	levels	 in	patients	with	
paraproteinaemias	to	prevent	unnecessary	investigations,	erroneous	diagnosis	and	potentially	
inappropriate	treatment.	
	
2.3.4 A	summary	of	Project	3		
	
These	 studies	 clearly	 showed	 significant	 variation	 in	 laboratory	 results	 due	 to	 pre-existing	
conditions,	 with	 the	 pre-existing	 condition	 causing	 an	 elevation	 in	 interferants	 that	 affect	
common	laboratory	tests.	I	demonstrate	that	a	possible	source	of	variation	may	be	due	to	the	
excess	presence	of	an	analyte	which	is	secondary	to	the	primary	investigation,	such	as	lipaemia	
or	haemolysis	affecting	liver	function	tests.	My	work	also	deals	with	the	solutions	for	dealing	
with	 this	 potential	 interferants.	 These	 papers	 have	 been	 cited	 52	 times	 in	 biochemical	 and	
disease	specific	journals,	of	interest	is	the	citing	of	the	papers	in	texts	on	effect	on	analytes	not	
covered	 in	my	work	 (such	 as	 the	 effect	 of	 lipaemia	 on	 caeruloplasim),	 the	 relevance	 in	 and	
implications	of	 investigation	of	 the	clinical	 conditions	 (rheumatoid	arthritis	and	antipsychotic	
medication).	
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2.4 Additional	studies	
	
These	two	studies	demonstrate	how	the	high	variability	in	CRP	would	render	it	ineffective	in	its	
incorporation	 into	 coronary	 heart	 disease	 risk	 assessment	 and	 the	 effect	 of	 inappropriate	
equipment	 selection	 for	 the	 diagnosis	 of	 hypoglycaemia	 and	 how	 it	 can	 lead	 to	 inaccurate	
results	and	therefore	unnecessary	investigations	
	
	
2.4.1 High	 variability	 in	 CRP	 and	 the	 effectiveness	 of	 its	 incorporation	 into	 CHD	 risk	
assessment	
	
CRP	 at	 the	 time	 of	 study	 was	 being	 proposed	 as	 a	 suitable	 marker	 for	 CVD	 screening	 and	
assessment.	 Proposed	 role	 were	 put	 forward	 that	 necessitated	 low	 non-pathophysiological	
variability,	especially	at	the	low	concentrations	observed	in	CVD.	
	
Therefore	for	this	study,	 I	wanted	to	make	an	observation	about	the	 limited	clinical	utility	of	
single	 hs-C-reactive	 protein	 (CRP)	 measurement	 in	 coronary	 heart	 disease	 (CHD)	 risk	
assessment	 (103).	 	 It	has	been	 suggested	 that	CRP	values	 can	be	 incorporated	 into	CHD	 risk	
assessment	 to	 improve	 prediction	 of	 CHD	morbidity	 (104).	 	 Assessment	 of	 CHD	 risk	 usually	
involves	opportunistic	screening	in	primary	care	(105).		
	
2.4.1.1	Materials	and	Methods	
I	measured	hs-CRP	by	immunoassay	(DPC,	Los	Angeles	CA,	USA)	in	434	subjects	from	primary	
care	in	whom	a	laboratory-based	CHD	risk	score	calculation	had	been	requested.			
	
2.4.1.2	Results	
	113	 (26.0%)	 subjects	 had	 hs-CRP	 concentrations	 above	 6.0	mg/L	 detection	 limit	 of	 ordinary	
CRP	assays)	and	32	subjects	(7.3%	had	CRP	values	>15	mg/L,	suggesting	an	active	inflammatory	
process	probably	due	to	a	minor	illness.			
	
2.4.1.3	Summary	and	significance	
These	results	suggest	that	using	CRP	during	opportunistic	screening	may	falsely	increase	CHD	
risk	 score,	 leading	 to	 inappropriate	 patient	 management.	 Furthermore,	 inflammatory	
processes,	indicated	by	elevated	CRP,	may	be	associated	with	lowering	of	total	cholesterol	and	
high	density	cholesterol	concentrations	(106),	which	may	in	turn	influence	calculated	CHD	risk	
scores.	 	 The	 results	 have	 shown	 that	 a	 significant	 number	of	 patients	who	have	undertaken	
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opportunistic	 screening	may	have	minor	or	 subclinical	 illness	 that	could	affect	 their	CHD	risk	
scores	and	adversely	influence	their	management.		Health	care	practitioners	should	be	aware	
of	 the	 potential	 limitations	 of	 the	 use	 of	 CRP	 and	 opportunistic	 screening	 in	 CHD	 risk	
assessment.	
	
	
2.4.2 Inappropriate	 assay	 selection	 causes	 increased	 variation	 in	 results	 and	 possible	
misinterpretation	of	results.	
	
This	paper	was	a	 series	of	 three	 case	histories	demonstrating	glucose	meter	hypoglycaemia.	
These	 highlighted	 the	 risk	 of	 using	 equipment	 with	 an	 inappropriate	 assay	 sensitivity	 to	
demonstrate	low	blood	glucose.		
	
This	work	was	particularly	 relevant	at	 the	time	because	glucose	meter	 technology	was	novel	
and	 was	 optimised	 for	 the	 intended	 use	 at	 high,	 or	 diabetic,	 glucose	 concentrations.	 The	
meters	 were	 no	 optimised	 for	 low	 concentrations,	 even	 though	 hypoglycaemia	 in	 diabetic	
patients	is	not	uncommon.		
	
The	 diagnosis	 of	 hypoglycaemia	 depends	 upon	 the	 demonstration	 of	 a	 low	 blood	 glucose	
concentration	 during	 a	 spontaneous	 symptomatic	 episode.	 Glucose	monitoring	 devices	may	
misdiagnose	many	healthy	individuals	with	nonspecific	symptoms	as	having	hypoglycaemia.	
	
2.4.2.1 Case	1	
	
A	31-year-old	housewife	gave	a	20-year	history	of	intermittent	fatigue	and	`shakes’	unrelated	
to	food	or	exercise.	She	attributed	these	symptoms	to	hypoglycaemia	when	a	nurse	recognized	
the	`symptoms	of	hypoglycaemia’	and	checked	her	capillary	blood	glucose	on	a	meter,	which	
gave	 a	 low	 reading	 (1.9mmol/L)	 (unconfirmed	 however	 by	 laboratory	measurement)	 during	
inpatient	investigations	for	abdominal	pain	1	year	previously.	
	
Her	GP	then	provided	her	with	blood	glucose	reagent	strips.	She	visually	recorded	her	glucose	
being	as	low	as	1±2mmol/L	when	symptomatic,	and	was	therefore	referred	for	assessment.	
During	 an	 exercise	 test	 following	 an	 18-h	 fast	 her	 plasma	 venous	 glucose	 rose	 from	 4.3	 to	
4.7mmol/L	and	her	 insulin	concentrations	were	 low,	at	525	pmol/L.	During	a	prolonged	(5-h)	
75	 g	 glucose	 load	 test	 her	 nadir	 plasma	 venous	 glucose	was	 5.5mmol/L	 at	 240min,	 but	 she	
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experienced	 `shakes	 and	 tiredness’	 when	 her	 plasma	 venous	 glucose	 was	 6.9mmol/L	 at	
180min.	 I	explain	that	hypoglycaemia	was	unlikely	to	explain	her	symptoms.	 I	suggested	that	
she	 should	have	a	blood	 sample	 collected	when	 symptomatic	 and	 taught	her	how	 to	 collect	
capillary	blood	into	a	fluoride	capillary	tube.	She	was	unhappy	with	our	explanation	and	never	
re-attended.	
	
2.4.2.2 Case	2	
	
A	 29-year-old	 female	 nurse	 gave	 a	 3-year	 history	 of	 intermittent	 disorientation,	 sweats	 and	
lethargy	unrelated	to	food	or	exercise.	While	at	work,	during	two	of	these	attacks	finger-prick	
blood	 samples	 gave	 low	 glucose	 meter	 readings	 (2.0mmol/L).	 She	 was	 referred	 for	 further	
assessment.	An	exercise	 test	 following	 an	18-h	 fast	 and	a	 5-h	75	 g	 glucose	 load	 test,	 during	
which	 she	 was	 asymptomatic,	 provided	 no	 evidence	 for	 hypoglycaemia.	 During	 one	 of	 her	
symptomatic	episodes	a	glucose	meter	 reading	was	1.1mmol/L,	but	simultaneously	collected	
laboratory	capillary	blood	glucose	was	5.5mmol/L.	She	accepted	that	her	symptoms	were	not	
due	to	hypoglycaemia	and	that	her	previous	readings	were	due	either	to	faulty	technique	or	to	
a	faulty	meter.	
	
2.4.2.3 Case	3	
	
While	 at	work	 during	 a	 period	 of	 personal	 stress,	 a	 24-year-old	 female	 nurse	 felt	 dizzy	with	
sweats,	nausea	and	 `shakes’.	A	nursing	colleague	using	a	glucose	meter	 found	her	 to	have	a	
reading	of	1.6mmol/L.	She	was	therefore	given	oral	glucose,	which	 led	to	a	resolution	of	the	
symptoms	 after	 30min.	 During	 a	 further	 similar	 attack	 3	 months	 later	 she	 was	 seen	 in	 an	
Accident	 and	 Emergency	 department	 with	 a	 label	 of	 hypoglycaemia	 and	 her	 glucose	meter	
reading	 was	 confirmed	 as	 `low’.	 She	 was	 given	 oral	 glucose	 and	 discharged	 with	
recommendations	that	she	be	investigated	further.	An	exercise	test	following	an	18-h	fast	and	
a	5-h	75	 g	 glucose	 load	 test,	 during	which	 she	was	 asymptomatic,	 provided	no	evidence	 for	
hypoglycaemia.	 I	explained	that	her	symptoms	were	unlikely	to	be	due	to	hypoglycaemia.	As	
her	personal	stress	resolved	she	had	no	further	symptomatic	episodes.	
	
2.4.2.4 Summary	and	significance	
	
Glucose	 meters	 are	 justifiably	 popular	 and	 have	 advanced	 the	 management	 of	 diabetic	
patients.	 However,	 glucose	 meters,	 and	 especially	 visually	 read	 glucose	 test	 strips,	 are	
unsuitable	 for	 the	diagnosis	of	 spontaneous	hypoglycaemia	 in	 the	domestic	environment,	 as	
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many	 of	 the	methods	 used	may	 be	 unreliable	 in	 the	 hypoglycaemic	 range	 (107-108).	 Faulty	
meters,	faulty	blood	strips,	faulty	patient	preparation	and	faulty	analytical	technique	may	also	
add	to	the	considerable	risk	of	erroneous	results	(109).	Glucose	meters	may	however	be	useful	
in	the	clinical	environment	(e.g.	 in	Accident	and	Emergency	departments)	as	a	rapid	guide	to	
the	 need	 for	 further	 blood	 collection	 (for	 confirmation	 and	 further	 investigation),	 followed	
immediately	by	the	administration	of	glucose	to	relieve	symptoms.	
	
In	 the	 cases	 described	 here	 the	 subjects	 were	 initially	 `investigated’	 in	 three	 different	
hospitals,	suggesting	that	`hypoglycaemia’	was	diagnosed	using	different	types	of	meter.	This	
suggests	 that	 any	 errors	 were	 probably	 due	 to	 faulty	 technique,	 but	 does	 not	 exclude	
instrument	or	reagent	error.	It	also	implies	that	the	use	of	glucose	meters	to	investigate	vague	
symptoms	 for	 hypoglycaemia	 may	 be	 widespread.	 It	 is	 likely	 that	 the	 simplicity	 and	 ready	
availability	 of	 glucose	 meters	 has	 led	 to	 their	 inappropriate	 use	 in	 the	 investigation	 of	
nonspecific	symptoms	for	the	possibility	of	hypoglycaemia.	An	important	adverse	consequence	
of	mislabelling	healthy	people	with	a	disease	is	a	reduction	in	their	quality	of	life,	and	in	some	
individuals	the	adoption	of	a	sick	role	(`the	worried	well’).	The	mislabel	of	`hypoglycaemia’	in	
these	patients	can	however	often	be	difficult	to	rectify,	perhaps	because	patients	who	present	
with	symptoms	of	hypoglycaemia	may	have	abnormal	psychological	profiles	(110).		
	
The	misdiagnosis	of	hypoglycaemia	may	also	result	in	unnecessary	and	wasteful	investigations,	
and	may	 in	part	 explain	why	57%	of	 samples	 received	 in	a	 supra-regional	 laboratory	 for	 the	
investigation	 of	 hypoglycaemia	 were	 inappropriate,	 having	 glucose	 values	 of	 greater	 than	
3.0mmol/L	 (111).	 We	 suggest	 that	 the	 use	 of	 glucose	 meters	 to	 diagnose	 spontaneous	
hypoglycaemia	 (without	 laboratory	 confirmation)	 is	 inappropriate,	wasteful	of	 resources	and	
may	 adversely	 affect	 the	 health	 of	 the	 individual.	 Patients	 with	 symptoms	 suggestive	 of	
neuroglycopenia	should	be	appropriately	assessed	and	investigated.	I	recommend	that	training	
of	personnel	in	the	use	of	glucose	meters	should	include	the	inappropriateness	of	their	routine	
use	in	investigating	spontaneous	hypoglycaemia	in	non-diabetic	adults.	
	
It	 must	 be	 recognised	 that	 since	 publication	 glucose	 meter	 technology	 has	 developed	
considerably.	 It	 is	 now	 uncommon	 for	 meters	 not	 to	 be	 able	 to	 detected	 glucose	
concentrations	 in	 the	 hypoglycaemic	 range.	 However	 with	 the	 expansion	 of	 point	 of	 care	
testing	in	to	the	fields	of	virology	and	molecular	testing,	the	same	principles	hold.	What	is	the	
meter	 detecting	 and	what	 is	 the	 analytical	 range	 it	 covers?	Until	 that	 is	 elucidated	 for	 each	
point	of	 care	 test,	 there	 is	 a	 risk	of	 variability	 in	 test	 reporting	 that	healthcare	professionals	
need	to	be	aware	of.	
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2.4.3 A	summary	of	Project	4		
	
These	 two	 projects	 demonstrate	 how	 inappropriate	 test	 selection	 can	 cause	 increased	
variability	in	test	results	and	therefore	potentially	inappropriate	result	interpretation.	The	two	
projects	explore	the	inappropriate	incorporation	of	CRP	into	cardiac	risk	stratification	and	the	
inappropriate	 use	 of	 glucose	meters	 in	 the	 assessment	 of	 hypoglycaemia	 and	 the	 potential	
misinterpretation	of	results	that	could	arise	from	their	use.	These	projects	have	been	cited	14	
times	in	best	practice	guidelines	on	glucose	meters	and	clinical	guidelines	for	the	assessment	
of	hypoglycaemia,	additionally	in	a	paper	on	CRPs	role	in	cardiovascular	risk	assessment.		
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Abstract
Background We investigated whether increased protease activity explains the
increased in vitro degradation of intact parathyroid hormone (iPTH) observed in
serum when compared to EDTA plasma.
Methods Pre-dialysis blood samples for iPTH were taken from 11 patients with
chronic renal failure and collected into plain glass tubes, tubes containing 200 KIU/
mL aprotinin (a protease inhibitor) and EDTA tubes. All sample aliquots were
separated at 20 min, 1 h, 2 h, 4 h, 8 h and 24 h post collection.
Results Over 24 h, iPTH concentrations remained unchanged in EDTA tubes.
iPTH concentrations were significantly lower in both plain tubes (P50¢01) and
aprotinin tubes (P50¢001) at 24 h when compared to the baseline sample (20 min).
At 24 h, iPTH concentrations in EDTA tubes were higher than in plain tubes
(P50¢001) and aprotinin tubes (P50¢01). The addition of aprotinin to plain tubes
significantly reduced the degradation of iPTH (P50¢05) at 24 h.
Conclusion Aprotinin significantly reduces the in vitro degradation of iPTH in plain
tubes at 24 h from 24¢7% to 9¢6%. We suggest that increased protease activity
contributes to the decline in serum iPTH over time. As this is observed in serum and
not plasma it suggests that the increased protease activity may be due to the clotting
process.
Ann Clin Biochem 2003; 40: 188–190
Introduction
Stability studies on intact parathyroid hormone
(iPTH) have reported that any in vitro degradation of
iPTH in unseparated blood samples may be sample
tube- and time-dependent.1,2 The greater degradation
of iPTH observed in serum compared to EDTAplasma3
remains unexplained. Increased in vitro degradation of
iPTH has been reported in patients who have high
concentrations of circulating proteases.4 Additionally,
it has been demonstrated that the addition of protease
inhibitors may arrest the in vitro decline in iPTH over
24 h,2 but this may be assay- and sample population-
dependent.
Thrombin plays a signi¢cant in vivo role in platelet
aggregation as part of the clotting process. Initiation
of platelet aggregation requires protease-dependent
binding of thrombin to platelet thrombin receptors.5
This increase in protease activity may be responsible
for the in vitro degradation of PTH. We therefore
investigated whether the addition of aprotinin (a
potent protease inhibitor) in£uenced the in vitro
stability of serum iPTH in unseparated samples from
patients with chronic renal disease.
Materials and methods
We venesected 11 patients with chronic renal failure
prior to them receiving dialysis. Blood samples were
collected into 10-mL plain glass tubes (Z10/GN, LIP,
Equipment and Services Ltd, Shipley, UK), with and
without 2000 KIU of aprotinin (Bayer AG, Germany),
and 2¢7-mL EDTA tubes (Sarstead Monovet 2¢7mL KE,
Aktiengesellschaft & Co, Germany).
Samples were then transported to the laboratory on
ice and remained unseparated at room temperature
(17-238C) until centrifugation. At 20min (baseline),
1h, 2 h, 4 h, 8 h and 24 h, a 1-mL aliquot was taken
from each tube and centrifuged. The resultant super-
natant was frozen at7208C until analysis, which was
188 © 2003 The Association of Clinical Biochemists
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carried out in one batch using the DPC Immulite iPTH
assay (intra-assay coe¤cient of variation 4¢8) (LKPH,
Diagnostic Products Corporation, Los Angeles, CA,
USA) immediately following thawing of the aliquot.
Following logarithmic transformation, the data were
normally distributed. Statistical analysis of the trans-
formed data was by parametric repeat measures
ANOVA with Tukey- Kramer post-test comparison.
Results are given as pre-transformed data expressed as
median (95% con¢dence intervals).
Results
Concentrations of iPTH in each tube type over time are
shown in Table 1. The iPTH concentration in the plain
sample separated at 24 h was signi¢cantly lower than
in those separated at baseline (P50¢001), 1h
(P50¢001), 2 h (P50¢001), 4 h (P50¢001) and 8 h
(P50¢001). There were no signi¢cant di¡erences
between any other time points. Between baseline and
24 h the decline in iPTH in plain tubes was 24¢7%.The
iPTH value in the aprotinin sample separated at 24 h
was signi¢cantly lower than those separated at base-
line (P50¢01), 1h (P50¢001), 2 h (P50¢001), 4 h
(P50¢001) and 8 h (P50¢001). There were no signi¢-
cant di¡erences between any other time points.
Between baseline and 24 h the decline in iPTH in
aprotinin tubes was 9¢6%.Therewere no di¡erences in
iPTH concentrations between the EDTA samples
separated at any time point.
iPTH concentration was signi¢cantly lower in plain
tubes when compared with aprotinin tubes (P50¢05)
at 24 h. iPTH concentration was also signi¢cantly
lower in plain tubes (P50¢001) and aprotinin tubes
(P50¢01) when compared with EDTA tubes at 24 h.
There were no other signi¢cant between-tube di¡er-
ences at any other time points.
Discussion
The unchanged plasma iPTH concentrations in EDTA
tubes, left unseparated for up to 24 h in pre-dialysis
samples collected from patients with chronic renal
failure, con¢rms that iPTH is stable for up to 24 h in
unseparated EDTA samples.3 Although we found no
signi¢cant di¡erence in baseline results between any
of the tubes, Omar et al. reported signi¢cantly higher
baseline iPTH values in EDTA tubes compared with
plain tubes in samples collected from patients
attending a renal stone clinic.6These di¡erences could
be explained by the di¡erent mixture of PTH frag-
ments in each of the di¡erent sample populations,
which may have di¡erent in vitro stability.
In this study, serum iPTH concentrations were
stable when left unseparated for up to 8 h in plain and
aprotinin-containing tubes. The addition of aprotinin
to plain tubes signi¢cantly reduced the decline in
iPTH at 24 h. However, there was still signi¢cant
di¡erence in iPTH in aprotinin tubes when compared
with EDTA tubes at 24 h. Levin and Nesbit2 using the
Nichols Institute, Allegro iPTH assay, found that addi-
tion of two protease inhibitors (aprotinin and
leupeptin) eliminated the decline in iPTH that we
observed at 24 h when compared to EDTA tubes. It is
possible that the combination of protease inhibitors
confers greater protection against in vitro iPTH
instability. However, as both studies used di¡erent
iPTHassays and di¡erent study populations, this is not
clear.
Our ¢ndings suggest that increased protease
activity could explain, in part, the decline in serum
iPTH in blood samples left unseparated for greater
than 8 h. Aprotinin is a serine protease inhibitor and
probably acts in vivo by inhibiting the thrombin-
induced proteolytic activation of platelets.5 This
mechanism may explain the in vitro observation that
iPTH decline is observed in serum and not in EDTA
plasma, suggesting that the increased protease
activity may be due to the clotting process.
We conclude that plain and EDTA tubes are appro-
priate sample tubes for collection of iPTH in patients
with renal disease, if left unseparated for up to 8 h.
Increased protease activity may solely or partially
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Table 1. Intact parathyroid hormone concentrations (pmol/L) in different sample tubes against time
Time
Tube type
(h) Number of samples Plain Aprotinin EDTA
0¢3 11 46¢5 (20¢2-62¢4) 43¢7 (19¢1-61¢8) 51¢3 (20¢7-65¢6)
1 11 51¢7 (20¢6-61¢4) 45¢8 (20¢4-60¢0) 45¢8 (20¢6-62¢5)
2 11 47¢3 (19¢9-61¢7) 48¢9 (23¢3-62¢5) 52¢4 (21¢6-63¢4)
4 11 46¢6 (20¢9-65¢3) 47¢4 (20¢7-64¢2) 50¢8 (20¢9-67¢1)
8 11 46¢6 (20¢2-62¢9) 45¢0 (20¢6-64¢4) 53¢3 (22¢2-67¢8)
24 11 30¢7{{ (13¢9-48¢5) 34¢3{, c* (16¢9-56¢4) 49¢2, a***, b** (19¢9-63¢9)
Results are median (95% condence limits). Within-tubes, the only signicant differences observed compared with baseline (0¢3 h) were at 24 h:
{P50¢01, {{P50¢001. Between-tubes, the only signicant differences were observed at 24 h: a, EDTA compared to plain tube, ***P50¢001; b,
EDTA compared to aprotinin tube, **P50¢01; c, aprotinin tube compared to plain tube, *P50¢05.
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contribute to the decline in serum iPTH in blood
samples left unseparated for longer than 8 h.
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Stability of intact parathyroid hormone
in blood samples
We wish to comment on the recent study of
Walker and Seth, which reports that intact
parathyroid hormone (iPTH) in blood collected
into ethylenediaminetetraacetic acid (EDTA)
tubes is more stable at room temperature than
in blood collected into `plain’ tubes.1
We feel, however, that a clear distinction
needs to be made between plain serum tubes and
gel serum tubes (as used by Walker and Seth).
We have compared the stability of iPTH in
blood samples taken into gel tubes (Sarstead
Monovet 4.7 mL, Z GEL) and plain glass tubes
(Lip Z10/GN).
Blood was drawn from nine patients with
chronic renal failure before commencement of
haemodialysis. Immediately after venesection,
samples were split between the plain and the gel
tubes. Samples were then separated after 20 min
at room temperature and serum frozen at
7208C until assayed for iPTH using the DPC
Intact PTH assay on the Immulite automated
immunoassay analyser.
Intact PTH values were 13% higher (P50´01,
two-tailed paired t-test) in plain serum tubes
[mean (SD): 7´6 (2.57)pmol/L] than in gel serum
tubes [6´7 (2´19) pmol/L] (see Fig. 1). We suggest
that these differences in iPTH values are
attributable to the gel barrier or clot activator
or both, especially since these results are
consistent with other studies reporting a similar
`gel effect’ on other immunoassays.2
DPC also recommended that blood samples
when collected into EDTA should ®ll the tube.
Otherwise, the EDTA concentration in the
sample will proportionately increase, affecting
the Immulite substrate alkaline phosphatase
reaction and thus lowering the iPTH result.
These factors may help explain both the
variation between EDTA plasma and (gel) serum
as reported1 and the differences between this
study, which reports that `serum’ iPTH collected
in gel tubes in unstable at 3 h,1 and other studies
which have reported that iPTH collected into
plain serum tubes is stable for up to 8 h.3,4
In conclusion, we suggest that differences by
Walker and Seth may be due to the gel separator
rather than to the differences between serum and
EDTA plasma. Further evaluation regarding
iPTH stability in whole blood is, therefore,
required.
N R ANDERSON
R GAMA
Department of Clinical Chemistry,
New Cross Hospital,
Wolverhampton WV10 0QP, UK
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Authors’ reply
Anderson and Gama correctly point out the
need to consider the potential effects of
separator gel in blood collection tubes on
immunoassay results and raise the question as
to whether this could account for the difference
we observed between EDTA plasma and serum
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FIGURE 1. Stability of intact PTH at room tempera-
ture. Blood was collected in plain serum tubes (1) and
gel tubes (2). All samples separated by 20 min and
serum stored at 7208C until analysis.
samples. We would ®rst acknowledge that our
short report did not make the type of serum tube
absolutely clear and we apologize for this. We
used white-capped Sarstedt S Monovettes (cat
no. 03.1397), which contain clotting activator
coated on plastic barrier beads but no gel, as
opposed to the brown-top tubes in the same
range which contain in addition a gel separator.
The differences we observed are not, therefore,
due to the presence of gel, or to the plastic beads,
as the samples were aliquoted into clean plastic
tubes within 15 min of collection, but could
indeed be due to the clotting activator. We can
con®rm, in the light of DPC’s recent recommen-
dation, that EDTA blood tubes should be ®lled
completely to avoid assay interference from high
concentrations of EDTA, and that we used fully
®lled EDTA blood tubes.
This recommendation from DPC, and Ander-
son and Gama’s observations, further emphasize
the need for laboratory and clinical staff to be
aware of the subtle (or in some cases not so
subtle) effects that blood collection systems can
have on PTH results. There is clearly no
substitute for checking the validity of the
particular combination of blood collection
system and PTH assay method used locally.
KAY WALKER
JOHN SETH
Department of Clinical Biochemistry,
Royal In®rmary of Edinburgh,
Lauriston Place,
Edinburgh EH3 9YW, UK
Effect of in¯ammatory response on trace
element and vitamin status
The statements by Sattar et al.1 on the nadirs of
serum zinc and selenium and their signi®cance
require clari®cation.
In support of our earlier cited references on
the 6 mmol/L lower limit for zinc, we report that
Halstead and Smith2 measured plasma zinc in
324 patients in 12 groups, with a variety of
disorders/conditions, and found minimum con-
centrations ranging from 5´8 mmol/L (liver
disease) to 11´9 mmol/L (tuberculosis). Although
Sattar et al.1 correctly report that the lowest
mean plasma zinc observed by Fraser et al.3 in
eight cardiac patients was 4´9+1´7 mmol/L, at
least part of this low value can be explained by
the haemodilution that occurs as part of the
coronary bypass procedure and which compli-
cates interpretation of changes in concentrations
of metalloproteins following cardiac surgery.
Their observed nadir in plasma zinc, which
occurred 9 h post-operatively, was accompanied
by a decrease in plasma copper from 18´3 to
13´3 mmol/L. This decrease must have involved
haemodilution since caeruloplasmin (copper) is
a positive acute phase reactant. The plasma
copper level returned to the pre-operative value
48h after surgery, at which time the mean plasma
zinc was 6´8+1´6 mmol/L and the C-reactive
protein concentration had peaked. 72 h post-
operatively, the mean zinc and copper concen-
trations were respectively 8´2 mmol/L and
20´3 mmol/L. These observations vindicate our
6´0 mmol/L lower limit for plasma zinc. More-
over, such transient changes would be avoided
by using our 3±5 day interval between monitor-
ing trace elements.4
Sattar et al.1 are correct; nadirs of 0´2 mmol/L
for plasma selenium have been observed in
intensive care unit (ICU) patients. Hawker et
al.5 reported plasma selenium concentrations for
175 ICU patients and found that only ®ve
(2´9%) had concentrations 40´3 mmol/L, and of
these three (1´7%) had levels below 0´2 mmol/L.
The lowest concentrations were seen in patients
with surgical sepsis and with decompensated
alcoholic liver disease. Forceville et al.6 also
observed plasma selenium levels as low as
0´2 mmol/L (and up to 0´72 mmol/L) in ICU
patients with severe sepsis and septic shock.
Thus, our limit of about 0´3 mmol/L appears at
®rst sight to be too stringent. However,
0´2 mmol/L is typical of selenium de®ciency in
Keshan disease-endemic areas (<0´25 mmol/L),7
and its ®nding in ICU patients is, to us and to
others,5,6 a cause for concern.
Forceville et al.6 gave selenium supplementa-
tion to their ICU patients with systemic immune
response syndrome and observed decreases in
plasma selenium in non-surviving patients and
slight increases in plasma selenium in surviving
patients. They concluded that a prolonged
decrease in plasma selenium could explain the
three-fold increase in morbidity and mortality in
patients with low plasma selenium (40´7 mmol/
L) on admission, compared with other ICU
patients. Although Hawker et al.5 concluded
that true selenium de®ciency was unlikely in
their ICU patients, they referred speci®cally to
their patients’ ®rst week in ICU. They went on
to say that `. . . true selenium de®ciency may
develop within the ®rst few weeks of an acute
illness’ and `. . . in the absence of supplementa-
tion, up to half of body selenium stores could be
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Ethnic differences in total and HDL cholesterol concentrations:
Caucasians compared with predominantly Punjabi Sikh
Indo-Asians
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Background Incomparison with Caucasians, Indo-Asians resident inthe UK have
similar total cholesterol but lower HOL cholesterol (HOLe) concentrations. It is
however possible that cardiovascular risk factors may vary between culturally
different Indo-Asians.
Methods We present data on 223 Indo-Asians (129 men, 94 women) and 787
Caucasians (421 men, 366 women) in whom a laboratory-based coronary heart
disease (CHO) risk score calculation had been requested.
Results Total cholesterol concentrations were similar in Indo-Asians and
Caucasians. HOLC concentrations were higher (P<O'001) in Caucasians [104
(1'3-104) mmol/L; median (95% confidence intervals)] than in Indo-Asians [1,2
(1·2-1·3)mmoI/L]. Indo-Asian women [1'2 (1·2-1·3) mmollL], Indo-Asian men [1,2
(1'2-1'3)mmoI/L] and Caucasian men [1,2 (1·2-1·3)mmoI/L] had similar HOLC
concentrations but these were all lower (P<O'001) than those in Caucasian women
[104 (1,3-1,4) mmoI/L).
Conclusion We confirm low HOLC concentrations inIndo-Asians, but propose that
this is solely due to low HOLC concentrations in Indo-Asian women. Since Indo-
Asians in Wolverhampton are predominantly Punjabi Sikhs. we suggest that the
difference between this stUdy and previous reports may be due to heterogeneity of
CHD risk factors within CUlturally diverse Indo-Asians.
Ann Clin Biochem 2002; 39: 609-611
An increased prevalence of coronary heart disease
(CHO) in Indo-Asians resident in the UK is unex-
plained by differences in cardiovascular risk factors of
hypercholesterolaemla, hypertension, smoking or a
family history of CHO.l ,2 Although diabetes mellitus is
more common in Indo-Asians. it does not fully explain
the increased prevalence of CHO.l ,2
Low serum HDLcholesterol (HOLC) concentrations.
widely reported in Indo-Asians. may contribute to the
increased prevalence of CHO amongst this group. 1,2
However, it has been suggested that there may be a
difference in cardiovascular risk factors between
culturally different Indo-Asian groups.' We therefore
compared serum total cholesterol (TC) and HOLC in
Indo-Asian and Caucasian subjects residing in
Wolverhampton. UK, for whom a laboratory CHO risk
assessment had been requested.
© 2002 The Association of Clinical Biochemists
Subjects and methods
We provide general practitioners (GPs) with a labora-
tory-based IO-year CHO risk score calculation based
on the Framingham equation." This calculation uses
the individual's age, sex. systolic blood pressure (BP).
TC concentration. HOLC concentration. and the
presence or absence of smoking. diabetes mellitus and
left ventricular hypertrophy. Clinical information was
collected from a sticker fixed on the pathology request
form. which also requested data on ethnicity (Cauca-
sian. Afro/Caribbean. Asian. Chinese and 'other'),
Patients were selected at the discretion of their GPs.
Since most laboratory CHDrisk assessment requests in
Indo-Asians were on subjects aged 40-60 years. we
restricted the study to this age group. Other exclusion
609
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Caucasian Indo-Asian P value
Table 1. Cardiovascular risk factors in Indo-Asians and
Caucasians
criteria included overt macrovascular disease and
lipid-lowering medication.
Serum TCand HDLC concentrations were measured
automatically (DiaSys Diagnostic Systems GmbH &Co.
Holzhelrn, Germany and Bio-Stat Diagnostic Systems.
Stockport. UK, respectively). Inter-assay and intra-
assay coefficients of variation for TC were respectively
1·22% and 0·61% and for HDLC were respectively
1·93% and O·75'X,.
Data were non-parametric. The Mann- Whitney
U-test was therefore used to assess the differences
between Indo-Asians and Caucasians. The Kruskal-
Wallis test with Dunn post-test comparison was then
used to assess the differences between ethnic male and
Results are medians (95% confidence intervals).
female subgroups. Results are expressed as medians
with 95% confidence intervals in parentheses.
Results
Complete demographic, clinical and biochemical data
sets were collected in 94 Indo-Asian women. 129
Indo-Asian men, 366 Caucasian women and 421
Caucasian men. Results are shown in Tables 1 and 2.
Serum TC concentration was similar in Caucasians
and Indo-Asians but Indo-Asians had a lower average
HDLC concentration (P<O'OOlj and therefore a
higher TC:HDLC ratio (P < 0,005). Men and women in
the two ethnic groups had similar TCconcentrations.
Indo-Asian women, Indo-Asian men and Caucasian
men had similar HDLC concentrations but these were
on average lower (P< D'OOl) than those in Caucasian
women. The TC:HDLC ratio was similar within each
gender group. Indo-Asian and Caucasian men had a
higher TC:HDLC ratio than did Caucasian women
(P < O'OOl) but a similar TC:HDLC ratio compared to
Indo-Asian women.
Discussion
We found that TC concentration in Indo-Asians and
Caucasians was similar and this is consistent with
previous studtes.l-' The lower HDLC concentration
found in Indo-Asians when compared with Cauca-
sians was consistent with previous studles.l-'
However, we suggest this is due to higher HDLC
concentrations in Caucasian women. since HDLC
concentrations were similar in Indo-Asian women.
Indo-Asian men and Caucasian men.
<0·0001
0·3055
<0·0001
0·0769
<0·0001
0·004
0·002
0·0714
787 223
52 49
(51,2-52,0) (48,9-50,5)
16·9 24·8
40·7 12·2
5·8 5·7
(5,7-5,9) (5,6-5,9)
104 1·3
(1'3-1-4) (1,2-1,3)
4·6 4·8
(4,5-4,7) (4,6-5,0)
140 136
(139-142) (133-138)
10·6 9·4
(10,1-11,2) (8,6-10,2)
-~~~~ ~-~~-~ ~~.
n
Age (years)
Diabetics (%)
Current smokers (%)
Total cholesterol
(mmoI/L)
HDL cholesterol
(mmoI/L)
Total:HDL cholesterol
ratio
Systolic BP (mmHg)
10-year CHD risk (%)
Table 2. Cardiovascular risk factors in women and men within the ethnic groups
Women Men
Caucasian Indo-Asian Caucasian Indo-Asian
n
Age (years)
Diabetics (%)
Current smokers (%)
Total cholesterol (mmoI/L)
HDL cholesterol (mmoI/L)
Totaf:HDL cholesterol ratio
Systolic BP (mmHg)
10-year CHD risk (%)
366
52
(50-7-51'8)
16·7
41·8b
5·8
(5'7~'0)
1'4bcd
(104-1'5)
4·0cd
(4·Q-4·4)
140b
(138-142)
7·7cd
(7,2-8'3)
94
49
(48,4-50'9)
21·3
08ed
5·4
(5,3-5'8)
1.28
(1,2-1'3)
4·5
(4,3-4,8)
1308C
(129-138)
5·6cd
(5,6-7'9)
421
52
(50,4-51'5)
20·7
48'4b
5·7
(5,6-5'9)
1.28
(1,2-1,3)
4.78
(4,7-5,1)
143b
(142-145)
13·5ab
(12'6-14,4)
129
49
(48,9-50,8)
27·1
20·9b
5·7
(5'~'0)
1·2a
(1,2-1'3)
4.98
(4,8-5,3)
140
(135-141 )
10·4ab
(10'4-12'5)
~----'---._._-------.~-.-"------- ..,.-..-----.----,.~ ----_.,'.__.-------_ .._-.-,,-----
~_ •. _ .'. ._ •. _. --'._-" ._0 __--.,.-.- _" __ • • ~. ••
. ---- ---------,..--- .', _._- .'.__....-..-.----_._.----_ .._.. --_ .. __._._--,---_ ..~-
Results are medians (95% confidence intervals). 'P<0'05 compared with Caucasian women; bp<0·05 compared with Asian women; cP<0·05
compared with Caucasian men; dp< 0·05 compared with Asian men. CHD=coronary heart disease.
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Previous studies have found higher HDLC concen-
trations in Caucasian and Indo-Asian women
compared with men. 5.6 The absence of a sex difference
in HDLC concentration in Indo-Asians in this study,
however. has been previously reported in some indi-
genous Indian communities 7 but this finding remains
unexplained. In women, the lower average HDLC
concentration in Indo-Asians, compared with those in
Caucasians, is unlikely in this study to be ethnic in
origin, since Indo-Asian men and Caucasian men had
similar HDLC concentrations. The lower HDLC
concentrations in Indo-Asian women may be related
to lifestyle (for example. exercise, menopausal status
and alcohol intake) or medication (e.g, oral contra-
ceptive pill or hormone replacement therapy). both of
which affect HDLC concentrations. It is also possible
that the higher than 'expected' HDLC in Indo-Asian
men may be likewise influenced by lifestyle factors.
It has been reported that there may be a variation of
CHD risk factors within culturally diverse Indo-
Asians.! In this study the Indo-Asian subjects were
predominantly Punjabi Sikhs. whereas other studies
have often included culturally diverse Indo-Asian
groups. The results in this study are consistent with a
previous study which observed similar HDLC concen-
trations in Sikh Indo-Asian men and Caucasian men
but lower HDL concentrations in Muslim and Hindu
Indo-Asian men," supporting the notion of diversity of
CHDrisk factors amongst Indo-Asians. 3
In conclusion, HDLC concentrations are lower in
Indo-Asian women that in Caucasian women but
similar in Indo-Asian men and Caucasian men. We
Ethnic differences in total and HDL cholesterol 611
suggest that this difference is likely to be social or
environmental in origin. In developing strategies to
prevent CHDin South Aslans.l-' consideration should
be given to possible diversity of CHD risk factors
between culturally different Indo-Asian groups.
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Abstract: Background and Aims: Studies in South Asian population show that low maternal 
vitamin B12 associates with insulin resistance and small for gestational age in the offspring. 
Low vitamin B12 status is attributed to vegetarianism in these populations. It is not known 
whether low B12 status is associated with metabolic risk of the offspring in whites, where 
the childhood metabolic disorders are increasing rapidly. Here, we studied whether maternal 
B12 levels associate with metabolic risk of the offspring at birth. Methods: This is a 
cross-sectional study of 91 mother-infant pairs (n = 182), of white Caucasian origin living 
in the UK. Blood samples were collected from white pregnant women at delivery and their 
newborns (cord blood). Serum vitamin B12, folate, homocysteine as well as the relevant 
metabolic risk factors were measured. Results: The prevalence of low serum vitamin B12 
OPEN ACCESS 
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(<191 ng/L) and folate (<4.6 μg/L) were 40% and 11%, respectively. Maternal B12 was 
inversely associated with offspring’s Homeostasis Model Assessment 2-Insulin Resistance 
(HOMA-IR), triglycerides, homocysteine and positively with HDL-cholesterol after 
adjusting for age and BMI. In regression analysis, after adjusting for likely confounders, 
maternal B12 is independently associated with neonatal HDL-cholesterol and homocysteine 
but not triglycerides or HOMA-IR. Conclusions: Our study shows that low B12 status 
is common in white women and is independently associated with adverse cord 
blood cholesterol. 
Keywords: vitamin B12; maternal; offspring; metabolic risk; lipids 
1. Introduction
The prevalence of childhood obesity is increasing rapidly [1,2]. Recently, the Early Childhood
Longitudinal Study demonstrated that 27.3% of children were either overweight or obese by the time 
they enter kindergarten in the United States [1]. Higher rate of childhood obesity is a likely contributor 
for the increasing incidence of type 2 diabetes (T2D) earlier in life as well as pre-gestational and 
gestational diabetes (GDM) in women [3]. It is known that childhood obesity independently predicts 
obesity and metabolic disorders in the adulthood [4]. Children born with lower HDL and higher 
triglyceride levels were small for gestational age (SGA) and had higher abdominal circumference [5]. It 
is known that both higher abdominal circumference and SGA are associated with future development of 
T2D and GDM [6,7] in many populations.  
Although current adverse lifestyle (nutrition and physical inactivity) contributes to obesity, a growing 
body of evidence links nutrient imbalance in early life to the development of metabolic disorders in 
childhood and in adults [8]. Many studies support this link including the Dutch-famine study. Individuals 
exposed to nutritional imbalance during pregnancy are likely to be obese, have early onset of coronary 
artery disease, T2D and worse cognitive performances as adults [9]. Emerging evidence from clinical 
studies show that key maternal micronutrients involved in the one-carbon metabolism (1-C) can cause 
adverse metabolic programming. Independent studies from South Asia have demonstrated that children 
born to mothers with low vitamin B12 [10,11] and higher folate [12] have greater insulin resistance. In 
addition, low maternal B12 levels independently contributed to the risk of small for gestational age 
(SGA), which has been shown to increase the metabolic risk of the offspring [13]. Vegetarianism is the 
likely cause of high prevalence of low B12 levels in these population [14]. In a Brazilian pregnancy 
cohort, low maternal B12 was associated with lower levels of the methyl donor (S-adenosyl 
methionine—SAM) in the cord blood [15]. A study in a Chinese population demonstrated that low 
maternal B12 is common during pregnancy and is associated with an altered methylation pattern of the 
insulin growth factor 2 (IGF2) promoter region in the cord blood [16], highlighting a potential role of 
B12 on fetal growth. Further, animal studies showed that maternal vitamin B12 deficiency resulted in 
higher adiposity, insulin resistance, blood pressure [17] and adverse lipid profile in the offspring [18,19]. 
These investigations provide evidence that low maternal B12 could be an independent determinant of 
adverse metabolic phenotypes in the offspring.  
Nutrients 2015, 7 2403 
Recently, we demonstrated in Europeans and Indians with T2D that vitamin B12 deficiency is 
associated with adverse lipid profile [20]. Re-analysis of the UK National Diet and Nutrition Survey 
data showed that low vitamin B12 levels (<191 ng/L) is common in the adult population (10%) and in 
women of reproductive age (14%) [21]. Our preliminary study of white pregnant women showed that 
the rate of low B12 status was as high as 20% at 16–18 weeks of gestation [22].  
Despite the evidence that vitamin B12 deficiency is a potential contributor for adverse offspring 
metabolic phenotypes and the prevalence of low B12 status is increasing in White Caucasian population, 
the link between maternal B12 status and metabolic risk at birth is unexplored in the White Caucasian 
population. Therefore, the objective of our study was to investigate whether maternal B12 levels in white 
women independently associate with the metabolic risk at birth.  
2. Methods
2.1. Study Population 
The study was conducted in University Hospital Coventry Warwickshire (UHCW), Coventry, UK. 
All study participants were pregnant women delivering at 39–40 weeks of gestation. The Coventry local 
research ethics committee approved the study, and all patients gave written informed consent (Research 
Ethics Committees 07/H1210/141). Women with known chronic diseases were excluded. Maternal data 
including parity, smoking, BMI and birth weight were collected from pregnancy records. Folic acid 
supplement use collected but detailed dietary history was not recorded. Maternal BMI measured 
routinely at the first pregnancy visit (before 10 weeks of gestation). We collected 182 maternal venous 
and cord blood samples (91 mother-newborn pairs) at the time of delivery. Extrapolating from our 
preliminary studies [21,22], we anticipated around 20%–25% of the mothers to have low levels of 
vitamin B12 (<191 ng/L). To detect a similar proportion of low B12 status a sample size of 100–120 
was required. The samples were collected in the fasting state, in tubes without anticoagulant and 
centrifuged at 2000 rpm/10 min. Serum was separated, aliquoted and stored at −80 °C until analysis. 
2.2. Analytical Determinations 
Serum glucose, cholesterol, triglycerides, HDL cholesterol were determined using an auto analyser 
Synchron CX7 (Beckman Coulter, Fullerton, CA, USA) based on enzymatic colorimetric assays. Insulin 
was measured using Invitrogen ELISA kit (Camarillo, CA, USA) according to manufacturer’s 
instructions. LDL cholesterol was calculated using Friedewald formula. Insulin resistance (HOMA-IR) 
was calculated by the Homeostasis Model Assessment 2 computer model (HOMA2) using fasting insulin 
and glucose levels [10]. Serum B12 and folate were determined by electrochemiluminescent 
immunoassay using a Roche Cobas immunoassay analyzer (Roche Diagnostics UK, Burgess Hill, UK). 
Similar to other studies [20,23,24], we have used 191–663 ng/L for serum Vitamin B12 and 
4.6–18.7 μg/L for serum folate as normal range, respectively. The inter-assay coefficient of variations 
for B12 and folate were 3.9% and 3.7%, respectively. To avoid potential bias, all the biochemical 
analyses were conducted in a single batch to minimise assay variation. All the laboratory personnel were 
blinded and did not have any access to the clinical data. Serum homocysteine was determined by stable 
isotopic dilution analysis liquid chromatography (LC-MS/MS) [25] using a Waters Equity UPLC system 
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(Waters, Milford, CT, USA) coupled to an API 4000 tandem mass spectrometer (Applied Biosystems, 
Warrington, UK). Due to the uncertainty of defining deficiencies of serum vitamin B12 and folate levels 
during pregnancy and cord blood, the terms “low B12 status” and “low folate status” were used 
throughout the manuscript if the levels were below 191 ng/L and 4.6 μg/L, respectively. 
2.3. Statistical Analysis 
Continuous data are reported either as mean ± standard deviation (SD) or geometric mean with 95% 
confidence intervals (CI). Categorical data are reported in numbers (percentages). The distributions of 
the maternal and neonatal parameters such as vitamin B12, folate, cholesterol, triglycerides, HDL, LDL, 
glucose, insulin, HOMA-IR and homocysteine concentrations were skewed; these data were 
log-transformed before analyses. Student’s t-test was used for comparison of groups. Bivariate 
correlations were done using Pearson test. Variables that showed significant associations with dependent 
variable (neonatal metabolic risk factors) were included as independent variables in the multiple linear 
regression analyses. To facilitate comparison, dependent and independent variables were converted into 
standard deviation scores (SDS). The data are presented as SD change in offspring outcome per SD 
change in maternal vitamin B12, folate and homocysteine. Associations between maternal vitamin B12, 
folate and homocysteine concentrations and offspring outcomes were examined in multivariate linear 
regression using 3 models. Model 1: unadjusted; Model 2: adjusted for maternal age, BMI, glucose, 
insulin, parity, folic acid supplement use, smoking, vitamin B12, folate and homocysteine; Model 3: 
Model 2 + respective maternal variable. All tests were two-sided, and p values of <0.05 were considered 
to be statistically significant. All analyses were performed using SPSS Statistics version 21 (IBM Corp, 
Armonk, NY, USA). 
3. Results
3.1. B12, Folate and Homocysteine Status 
The clinical characteristics of mothers and neonates are shown in Table 1. The prevalence of serum 
low vitamin B12 and folate status in women during pregnancy were 40% and 11% in mothers and 29% 
and 0% in neonates, respectively (Table 1). In cord blood, all the biochemical parameters were 
significantly lower than in maternal serum, except for the B12 and folate levels (Table 1). Children born 
to mothers with low B12 status had significantly lower B12 levels compared to those born to mothers 
with normal levels (Table 2). Mothers with higher parity and smoking had lower B12 levels. Those with 
self-reported folic acid supplement use had higher B12 and lower homocysteine levels (Table 3). 
Maternal B12, folate and homocysteine showed strong positive correlation with the respective offspring 
indices (B12: r = 0.648, folate: r = 0.706, homocysteine: r = 0.756, all p < 0.0001) (Supplementary 
Figure S1a–c). Neonatal homocysteine showed negative correlation with maternal B12 and folate (B12: 
r = −0.409, p < 0.0001; folate: r = −0.346, p < 0.001; Supplementary Figure S2a,b). 
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Table 1. Clinical characteristics of mothers and neonate. 
Mother Neonate 
n = 91 n = 91 
Age (years) 32.7 ± 5.9 a - 
Weight (Kg) 77.7 ± 18.1 3.57 ± 0.26 
Height (m) 1.62 ± 0.09 - 
BMI (early pregnancy) (kg/m2) 29.4 ± 6.2 - 
Glucose (mmol/L) 4.37 ± 0.42 3.88 ± 0.52 
Insulin (mIU/L) 11.6 (12.9, 17.4) b 8.01 (8.62, 11.9) 
Triglycerides (mmol/L) 2.69 (2.62, 3.06) 0.23 (0.22, 0.26) 
Cholesterol (mmol/L) 6.48 (6.31, 6.89) 1.68 (1.63, 1.84) 
LDL cholesterol (mmol/L) 3.53 (3.46, 3.95) 0.82 (0.79, 0.95) 
HDL cholesterol (mmol/L) 1.56 (1.53, 1.72) 0.74 (0.72, 0.83) 
HOMA-IR 1.37 (1.55, 2.09) 0.99 (1.04, 1.41) 
Vitamin B12 (ng/L) 218 (213, 289) 290 (292, 418) 
Low B12 status (%)  36 (40) c 26 (29) 
Folate (μg/L) 10.5 (10.9, 13.2) 16.8 (16.4, 17.7) 
Low folate status (%) 10 (11) 0 
Homocysteine (μmol/L) 6.23 (6.02, 7.54) 5.76 (5.64, 6.85) 
a Mean ± SD (all such values); b Geometric mean (95% CI) (all such values); c Numbers (percentages) (all 
such values). 
Table 2. Clinical characteristics of mothers and neonate according to maternal B12 levels. 
Mothers Neonate 
Maternal B12 
≥191 (ng/L) 
Maternal B12 
<191 (ng/L) 
Maternal B12 
≥191 (ng/L) 
Maternal B12 
 <191 (ng/L) 
n = 55 n = 36 n = 55 n = 36 
Age (years) 33.0 ± 6.2 a 32.3 ± 5.6 - - 
Weight (Kg) 74.3 ± 15.8 82.9 ± 20.8 * 3.58 ± 0.31 3.57 ± 0.18 
Height (m) 1.62 ± 0.07 1.61 ± 0.11 - - 
BMI (early pregnancy) (kg/m2) 28.4 ± 6.1 30.8 ± 6.4 * - - 
Glucose (mmol/L) 4.40 ± 0.46 4.36 ± 0.34 3.85 ± 0.52 3.94 ± 0.52 
Insulin (mIU/L) 10.4 (11.7, 18.0) b 13.7 (12.7, 18.6) 8.27 (8.33, 12.75) 7.64 (7.30, 12.40) 
Triglycerides (mmol/L) 2.49 (2.37, 2.93) 3.04 (2.82, 3.48) * 0.21 (0.20, 0.24) 0.26 (0.23, 0.32) ** 
Cholesterol (mmol/L) 6.23 (5.99, 6.72) 6.86 (6.51, 7.43) * 1.72 (1.64, 1.92) 1.62 (1.51, 1.83) 
LDL cholesterol (mmol/L) 3.29 (3.16, 3.82) 3.91 (3.67, 4.38) * 0.79 (0.76, 0.90) 0.87 (0.77, 1.09) 
HDL cholesterol (mmol/L) 1.61 (1.54, 1.80) 1.49 (1.42, 1.70) 0.79 (0.76, 0.91) 0.67 (0.62, 0.77) * 
HOMA-IR 1.18 (1.37, 2.14) 1.68 (1.57, 2.27) 0.94 (0.95, 1.41) 1.08 (0.98, 1.63) 
Vitamin B12 (ng/L) 288 (265, 378) 146 (139, 155) *** 367 (354, 544) 202 (187, 234) *** 
Low B12 status (%) 0 36 (40) c 8 (14.5)  18 (50) 
Folate (μg/L) 11.7 (11.5, 14.6) 9.0 (8.5, 12.4) * 17.6 (17.0, 18.5) 15.7 (14.9, 17.2) ** 
Low folate status (%) 3 (5.5) 7 (19.4) 0 0 
Homocysteine (μmol/L) 5.50 (5.26, 6.18) 7.53 (6.69, 10.1) *** 4.97 (4.74, 5.59) 7.09 (6.58, 8.96) *** 
a Mean ± SD (all such values); b Geometric mean (95% CI) (all such values); c Numbers (percentages) (all such values); 
* p-value compared to maternal B12 (≥191 ng/L) group; * p < 0.05; ** p < 0.01; *** p < 0.001.
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Table 3. Vitamin B12, folate and homocysteine in mothers and neonate according to 
maternal smoking status, parity and folate supplement use. 
Smoking n = 91 
Vitamin B12 
(ng/L) 
Folate 
(μg/L) 
Homocysteine 
(μmol/L) 
Maternal 
No (%) 55 245 (227, 357) 10.7 (10.6, 13.9) 6.15 (5.61, 8.08) 
Yes (%) 45 189 (176, 224) ** 10.1 (9.7, 13.3) 6.33 (5.90, 7.45) 
Neonate 
No (%) 55 327 (305, 502) 16.9 (16.4, 18.2) 5.42 (5.06, 6.58) 
Yes (%) 45 252 (232, 364) * 16.5 (15.8, 17.7) 6.21 (5.80, 7.68) 
Parity 
Maternal 
Para 0 (%) 18 248 (203, 332) 13.7 (11.8, 17.9) 6.25 (5.21, 8.03) 
Para 1 (%) 48 224 (201, 347) 11.1 (10.8, 14.1) 6.12 (5.73, 7.43) 
Para ≥2 (%) 34 195 (179, 239) * 8.2 (7.6, 11.6) ** 6.4 (5.31, 8.97) 
Neonate 
Para 0 (%) 18 327 (264, 479) 17.9 (16.6, 19.6) 5.61 (4.50, 7.59) 
Para 1 (%) 48 284 (258, 487) 16.9 (16.3, 18.1) 5.91 (5.53, 7.30) 
Para ≥2 (%) 34 283 (250, 396) 16.0 (15.2, 17.4) * 5.67 (5.08, 7.15) 
Folate supplement users 
Maternal 
Yes (%) 85 224 (216, 305) 11.1 (11.3, 14.0) 6.06 (5.77, 7.44) 
No (%) 15 187 (154, 245) 6.8 (5.5, 9.3) *** 7.42 (6.02, 9.61) * 
Neonate 
Yes (%) 85 311 (306, 445) 17.4 (17.0, 18.2) 5.57 (5.40, 6.53) 
No (%) 15 213 (134, 391) 13.5 (12.0, 15.6) *** 7.01 (5.34, 10.33) * 
Data are geometric mean (95% CI); * p-value compared to geometric mean in the respective group(s); 
* p < 0.05; ** p < 0.01; *** p < 0.001.
3.2. Maternal B12 and Metabolic Risk of Offspring 
Maternal B12 adjusted for age and BMI was inversely associated with metabolic risk factors such as 
triglycerides (r = −0.219; p = 0.047), HOMA-IR (r = −0.232; p = 0.041), homocysteine (r = −0.423; 
p = 0.0001) and positively with HDL-cholesterol (r = 0.315; p = 0.004) (Figure 1a–d) in the offspring. 
Despite similar birth weight, offspring of low B12 mothers had significantly lower HDL-cholesterol, 
higher triglycerides and homocysteine than those of normal B12 mothers (Table 2). Multiple regression 
analysis was carried out to assess whether maternal B12 independently associated with these metabolic 
risk factors in the offspring by adjusting for likely confounders. The model included maternal age, parity, 
smoking, folic acid supplement use, BMI, glucose, insulin, folate and homocysteine as independent 
variables. In addition, for offspring’s lipid parameters, respective maternal variable was also included in 
the model (maternal triglycerides for offspring’s triglycerides, etc.). After all these adjustments, maternal 
B12 was independently associated with the offspring’s HDL and homocysteine. Though similar trends 
were seen for the triglycerides and HOMA-IR, these were not statistically significant. No sex-specific 
changes were seen in any of these analyses (data not shown). Maternal B12 explained 5.1% of the 
variation in offspring’s HDL and 10.6% in homocysteine (Table 4).  
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Table 4. Association of maternal B12, folate and homocysteine with neonate metabolic risk factors. 
Maternal 
Variable 
(SDS) 
Neonate’s Metabolic Risk Factors (SDS) 
Triglycerides * Cholesterol * HDL * LDL * Insulin * Glucose * Homocysteine * 
Maternal 
B12 * 
β 
95% 
CI 
p β 95% CI p β 95% CI p β 95% CI p β 95% CI p β 95% CI p β 
95% 
CI 
p 
Model 1 −0.148 
(−0.38, 
0.09) 
0.2
10 
0.10
9 
(−0.11, 
0.33) 
0.3
17 
0.29
6 
(0.07, 
0.52) 
0.0
10 
−0.0
44 
(−0.26, 
0.17) 
0.6
91 
0.07
0 
(−0.21, 
0.21) 
0.5
16 
−0.0
05 
(−0.22, 
−0.21) 
0.960 
−0.3
81 
(−0.58, 
−0.18) 
<0.001 
Model 2 −0.086 
(−0.38, 
0.21) 
0.5
62 
0.17
8 
(−0.08, 
0.44) 
0.1
73 
0.29
4 
(0.05, 
0.54) 
0.0
18 
0.07
0 
(−0.26, 
0.39) 
0.6
72 
−0.0
63 
(−0.17, 
0.29) 
0.5
93 
−0.0
88 
(−0.14, 
−0.31) 
0.438 
−0.2
00 
(−0.35, 
−0.05) 
0.009 
Model 3 −0.079 
(−0.39, 
0.23) 
0.6
09 
0.17
0 
(−0.09, 
0.43) 
0.1
98 
0.29
5 
(0.08, 
0.51) 
0.0
09 
0.05
6 
(−0.28, 
0.39) 
0.7
36 
−0.0
62 
(−0.17, 
0.29) 
0.6
02 
−0.0
93 
(−0.12, 
0.30) 
0.378 
Maternal Folate * 
Model 1 −0.109 
(−0.33, 
0.11) 
0.3
26 
−0.2
10 
(−0.42, 
0.001) 
0.0
51 
−0.0
25 
(−0.25, 
0.19) 
0.8
25 
−0.1
73 
(−0.38, 
0.04) 
0.1
11 
0.04
0 
(−0.17, 
0.25) 
0.7
05 
−0.1
24 
(−0.33, 
0.09) 
0.243 
−0.3
27 
(−0.53, 
−0.13) 
0.002 
Model 2 −0.084 
(−0.43, 
0.26) 
0.6
25 
−0.2
04 
(−0.49, 
0.08) 
0.1
60 
−0.2
36 
(−0.51, 
0.04) 
0.0
91 
−0.0
79 
(−0.40, 
0.24) 
0.6
25 
0.13
3 
(−0.15, 
0.42) 
0.3
57 
−0.0
35 
(−0.31, 
0.24) 
0.799 
−0.0
04 
(−0.19, 
0.18) 
0.966 
Model 3 −0.093 
(−0.45, 
0.26) 
0.6
00 
−0.2
00 
(−0.49, 
0.09) 
0.1
69 
−0.2
09 
(−0.46, 
0.04) 
0.0
99 
−0.0
82 
(−0.41, 
0.24) 
0.6
16 
0.13
6 
(−0.15, 
0.43) 
0.3
53 
−0.0
39 
(−0.29, 
0.22) 
0.763 
Maternal Homocysteine * 
Model 1 0.218 
(−0.00, 
0.44) 
0.0
50 
0.29
0 
(−0.07, 
0.51) 
0.0
09 
0.11
9 
(−0.13, 
0.36) 
0.3
36 
0.26
5 
(0.06, 
0.47) 
0.0
13 
0.00
1 
(−0.21, 
0.21) 
0.9
93 
0.12
1 
(−0.09, 
0.34) 
0.269 
0.75
2 
(0.62, 
0.89) 
<0.001 
Model 2 0.137 
(−0.19, 
0.47) 
0.4
73 
0.20
6 
(−0.08, 
0.49) 
0.1
56 
0.09
3 
(−0.23, 
0.41) 
0.5
56 
0.22
4 
(−0.09, 
0.54) 
0.1
60 
0.03
7 
(−0.23, 
0.31) 
0.7
85 
0.05
7 
(−0.21, 
0.32) 
0.669 
0.69
6 
(0.52, 
0.87) 
<0.001 
Model 3 0.126 
(−0.23, 
0.48) 
0.4
74 
0.23
0 
(−0.07, 
0.53) 
0.1
29 
0.15
8 
(−0.13, 
0.45) 
0.2
78 
0.24
8 
(−0.08, 
0.57) 
0.1
30 
0.04
3 
(−0.24, 
0.32) 
0.7
59 
0.08
9 
(−0.16, 
0.34) 
0.469 
* Log transformed for statistical comparisons. β represents SDS change in the dependent variable per SDS change in the independent variable. Model 1: unadjusted; Model 2: Maternal age,
BMI, glucose, insulin, parity, folic acid supplement use, smoking, vitamin B12, folate and homocysteine; Model 3: Model 2 + respective maternal variable such as a—Model 2 + maternal 
triglycerides, b—Model 2 + maternal cholesterol, c—Model 2 + maternal HDL, d—Model 2 + maternal LDL, e—Model 2 + maternal insulin, f—Model 2 + maternal glucose, g—Model 2 + 
maternal homocysteine. 
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Figure 1. Correlation between maternal B12 (adjusted for age and BMI) and metabolic risk 
factors of neonates. (a) Maternal B12 and neonatal triglycerides, (b) Maternal B12 and 
neonatal Homeostasis Model Assessment 2-Insulin Resistance (HOMA-IR), (c) Maternal 
B12 and neonatal homocysteine, (d) Maternal B12 and neonatal HDL. * Log-transformed 
for statistical comparisons.  
3.3. Maternal Folate and Homocysteine and Metabolic Risk of Offspring 
Maternal folate negatively associated with offspring’s cholesterol (r = −0.214; p = 0.045), LDL 
(r = −0.233; p = 0.030) and homocysteine (r = −0.346; p = 0.001). Maternal homocysteine positively 
associated with offspring’s triglycerides (r = 0.239; p = 0.030), cholesterol (r = 0.247; p = 0.022) and 
LDL (r = 0.244; p = 0.026), however, these associations diminished after adjusting for all likely 
confounders (Table 4). 
4. Discussion
Our study is the first to show that maternal vitamin B12 levels adversely associated with markers of
metabolic risk at birth, in particular lipid profiles. Our observed rates of low B12 status in mothers (40%) 
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is common at the time of delivery though it is not as high as in the South Asian population [10,11,26]. 
Haemodilution and increased nutrient demand by the growing fetus [27] are known contributors to low 
B12 levels during pregnancy. In addition, consumption of processed foods, improving hygiene and 
reheating of cooked food, all known to reduce the bioavailable B12 in food products, could have 
contributed to lower B12 levels in this population [20,28]. The presence of higher homocysteine in the 
low B12 group suggest that these low levels are clinically significant and represent true insufficiency at 
the tissue level.  
Our findings show that low maternal B12 status was associated with offspring’s insulin resistance, 
lower HDL and higher triglycerides (Figure 1a,b,d). However, when multivariate analysis was used to 
assess the effect of B12 across the spectrum, only HDL was statistically significant after adjusting for 
the possible confounders (Table 4). In support of this, adverse lipid profile (higher total cholesterol and 
triglycerides) was noticed in rats born to vitamin B12 restricted dams [18,19]. In addition, we have 
recently demonstrated that adipocytes cultured in low B12 condition showed increased cholesterol levels 
and was due to hypomethylation of cholesterol transcription factor (SREBF1 and LDLR) [29]. The 
clinical findings observed in this study thus add evidence that low maternal B12 status adversely affects 
lipid profile in the offspring. We did not see any significant association between maternal and neonatal 
lipids (data not shown). While this was surprising, it was similar to other observations, where only lipids 
from GDM mothers associated with foetal lipids and not from non-GDM mothers [30,31].  
Our study also showed that maternal B12 showed a stronger inverse association with neonatal 
homocysteine than folate (Supplementary Figure S2a,b). In multiple regression analysis, after adjusting 
for the possible confounders, only maternal B12 and not folate, was independently associated with 
neonatal homocysteine (Table 4). The association between maternal folate and neonatal homocysteine 
became insignificant, when maternal homocysteine was added in the stepwise regression model 
(Table 4). This suggests that the effect of folate on neonatal homocysteine is likely to be mediated 
through maternal homocysteine while the effect of B12 could be partly independent of maternal 
homocysteine. Similar to our findings, Molloy et al. showed in an Irish population that low maternal 
B12 levels predicted hyperhomocysteinemia in both the newborns and the mothers [32]. Thus, our 
findings confirm that in folate replete populations, B12 is the strongest driver of homocysteine [10], an 
established metabolic risk factor [33]. Our study also showed that the BMI was higher in the low B12 
group (Table 2). Similar observations were seen other studies [29–31]. The cause and effect of this 
relationship is not known. Theoretically this could have contributed to higher maternal lipids and in turn 
higher lipids in cord blood. However, we did not see any correlation between maternal and cord lipids 
and our regression analysis adjusted for maternal lipids (Table 4). 
The plausible biochemical reasons that low maternal B12 status increase the metabolic risk in the 
offspring might be, firstly, in the cytoplasm, vitamin B12 acts as a cofactor for conversion of 
homocysteine to methionine, the direct precursor of S-adenosylmethionine (SAM) which is the common 
donor required for methylation of DNA, protein and lipids [10,26,34]. Secondly, in mitochondria, 
vitamin B12 also acts a cofactor for the conversion of methylmalonyl Co-A (MM-CoA) to succinyl 
Co-A. Thus, low vitamin B12 causes higher MM-CoA levels. This in turn can inhibit carnitine palmitoyl 
transferase-1 (CPT-1), the rate-limiting enzyme for fatty acid β-oxidation, thereby increasing 
lipogenesis [10,35]. As these mechanisms involve methylation of DNA, this might lead to higher 
metabolic risk in the offspring by adverse epigenetic programming in addition to directly affecting β-
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oxidation of fatty acids. In vivo and interventional studies are required to identify the exact mechanisms 
and prove the causality. 
Similar to B12, low maternal folate levels also showed adverse correlations with the metabolic risk 
markers of the offspring but these differences disappeared in regression models. Women with highest 
B12 and folate levels gave birth to children with lowest homocysteine levels compared to those with 
lowest B12 and folate levels (7.80 vs. 4.85 μmol/L, p < 0.001; Supplementary Table S1). Taken together, 
these findings suggest that optimising the circulating levels of these two B vitamins during pregnancy, 
is likely to be beneficial to the offspring.  
Strengths and limitations: Our study is cross sectional and from a single-centre. However, this is the 
first study to report the associations between maternal B12 and lipid profiles in the offspring. A 
prospective cohort of women from before or early pregnancy would have been a better model. As the 
pathophysiological link, if any, between maternal nutrient status and offspring metabolic risk seem to 
happen earlier in pregnancy, such longitudinal study would have strengthened our findings [9,10]. Our 
findings call for such studies to be conducted urgently. Studies have reported that B12 levels 
progressively decline during pregnancy [36]. Therefore, the effect size we observed during late 
pregnancy might have been an overestimate if early pregnancy samples were tested. We did not use the 
microbiological assay for B12 measurements, which is known to be more sensitive at the lower levels 
of B12. This may have underestimated the rate of low B12 status [37] and in turn, the association with 
the metabolic risk factors in the offspring. We did not have a detailed socioeconomic status of the 
participants. It is known that lower socioeconomic status is an important confounder of adverse lipid 
profiles and BMI but the link between socioeconomic status and B12 is not known. Therefore, this is 
also a limitation of our observation and future studies should collect detailed socioeconomic status. 
Finally, although our sample size was adequate to demonstrate the low B12 status, it was probably too 
small to demonstrate the independent associations between maternal folate and homocysteine status and 
cord blood lipids. 
In summary, our study shows that maternal vitamin B12 plays an important role in lipid metabolism 
in the offspring and that their restriction in utero may predispose them to the increased metabolic risk. 
However, these findings need to be replicated, ideally in a larger cohort of pregnant women from early 
pregnancy. In addition, in vivo and interventional studies are required to prove the exact mechanisms and 
the potential causal link. If proven, optimizing B12 levels of young women around the peri-conceptional 
period, could offer novel opportunities to reduce the burden of obesity and related metabolic disorders 
of the next generation. 
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Concise report
Raised serum prolactin in rheumatoid arthritis:
genuine or laboratory artefact?
S. Ram, D. Blumberg1, P. Newton1, N. R. Anderson and R. Gama
Objectives. Serum prolactin concentrations have been reported as higher, similar or lower in patients with rheumatoid
arthritis (RA) compared with control subjects. We investigated whether low biological activity macroprolactin (a prolactin
antibody complex), which is detected variably in different prolactin immunoassays, could account for the discrepant
total prolactin results reported in RA.
Methods. We compared serum total prolactin and free prolactin in 60 women with RA and 31 female controls.
Results. No subject had hyperprolactinaemia or macroprolactinaemia. Serum concentrations of total and free (monomeric)
prolactin were higher (P<0.05) in women with RA [mean (S.D.), 225.6 (104.6) and 201.6 (95.4) mU/l respectively] compared
with controls [175.0 (68.5) and 154.0 (60.9) mU/l respectively].
Conclusions. We report higher serum free prolactin concentrations in women with RA compared with control subjects.
This result indicates that the higher serum total prolactin levels in patients with RA are the consequence of increased free
prolactin concentrations and are not due to macroprolactin.
KEY WORDS: Prolactin, Macroprolactin, Big prolactin, Big big prolactin, Rheumatoid arthritis.
It has been suggested that prolactin may have a pathogenetic
role in rheumatoid arthritis (RA), since in vitro studies have shown
that prolactin enhances inﬂammatory responses [1–4]. Indeed,
increased serum prolactin concentrations have been reported in
patients with RA [5–10]. Furthermore, dopamine agonists, which
suppress pituitary secretion of prolactin, may be a useful adjunct to
treatment in patients with RA [11–13]. Prolactin circulates in
several different molecular forms, predominantly monomeric
prolactin but also as small but variable amounts of ‘big prolactin’
and ‘big, big prolactin’ (macroprolactin). The binding of prolactin
to an immunoglobulin forms macroprolactin. Since macropro-
lactin is less physiologically active and is less effectively cleared
than free unbound prolactin, the total concentration of serum
prolactin increases. Depending on the immunoassay used, macro-
prolactin may account for 4–5% of cases of hyperprolactinaemia
[14, 15] and has also been reported in normoprolactinaemic
samples [16].
Systemic lupus erythematosus (SLE), an autoimmune disease
with an increased prevalence of serum autoantibodies, is associated
with macroprolactinaemia [16, 17]. RA is also associated with an
increased frequency of circulating antibodies and macroprolactin
has been reported in patients with RA [18]. It is therefore possible
that macroprolactin could account for the hyperprolactinaemia
observed in RA, particularly since increased serum prolactin in
RA has been reported in most [5–10] but not all [19–23] studies,
possibly due to the use of different prolactin assays with varying
macroprolactin cross-reactivity [24, 25].
This is the ﬁrst report investigating the contribution of low
biological activity macroprolactin to circulating prolactin in RA
by comparing total and free (monomeric) prolactin concentrations
in women with and without RA.
Material and methods
Patients
Sixty women with RA and 31 women with osteoarthritis, who
served as controls, were studied. A blood sample for serum
prolactin was collected at least 2 h after awakening, between
09.30 and 12.00 h. Exclusion criteria included endocrine and any
other disease or medication known to affect serum prolactin con-
centrations. All women gave informed written consent according
to the Declaration of Helsinki to participate in this study, which
was approved by the Wolverhampton District Local Research
Ethics Committee.
Analytical methods
Polyethylene glycol (PEG) was used to precipitate and remove
big prolactin and macroprolactin from serum samples [26, 27].
Serum prolactin was therefore measured before (total prolactin)
and after (free or monomeric prolactin) precipitation with PEG
6000 [27] using the Architect prolactin assay (Abbott Laboratories,
Diagnostics Division, IL, USA). Respective inter-assay and intra-
assay coefﬁcients of variation for serum prolactin were 4.7 and
3.8%.Prolactin recovery<40%is indicative ofmacroprolactin [27].
Statistical analysis
Data were normally distributed. Unpaired and paired Student’s t
tests were therefore used to assess differences in variables between
groups and within groups respectively. Results are expressed as
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mean (S.D.). Pearson’s linear correlation was used to measure the
signiﬁcance of association between variables.
Results
Demographic, clinical and biochemical data are shown in Table 1.
No subjects had hyperprolactinaemia or macroprolactinaemia.
Serum concentrations of total and free (monomeric) prolactin
were higher (P<0.05) in women with RA [225.6 (104.6) and 201.6
(95.4) mU/l respectively] than in controls [175.0 (68.5) and 154.0
(60.9) mU/l respectively]. Although serum prolactin fell following
PEG precipitation in women with RA and controls, this was not
signiﬁcant (P¼ 0.1936 and P¼ 0.2877 respectively).
In women with RA, there were no correlations between
ESR and total prolactin (r¼ 0.1163; P¼ 0.3762) or free prolactin
(r¼ 0.07725; P¼ 0.5574), but ESR inversely correlated with the
percentage of free prolactin of the total prolactin (r ¼0.3278;
P¼ 0.0106).
Discussion
Although no subjects in this study had hyperprolactinaemia, we
report higher serum prolactin concentrations in women with RA
compared with controls. This result is consistent with other studies
similarly reporting higher total prolactin concentrations in patients
with RA than in controls [5–10], but differs from studies reporting
similar [19, 20] or lower [21, 22] prolactin concentrations in
patients with RA. In addition we report for the ﬁrst time higher
free prolactin concentrations in subjects with RA. It is therefore
unlikely that the different total prolactin concentrations reported
in various studies are solely due to varying macroprolactin cross-
reactivity in different prolactin assays. The difference in these
studies, however, could be due to selection of patient groups and
type 1 and 2 statistical errors.
Macroprolactinaemia is well recognized in SLE [16, 17] and the
difference in the prevalence of macroprolactinaemia between SLE
and RA may be related to the type of circulating immunoglobulin
(Ig). Macroprolactin is usually formed by the binding of prolactin
to an IgG antibody. In RA the predominant circulating immu-
noglobulin is an IgM antibody, which may not bind to prolactin.
Prolactin has a role in immunomodulation and it has been
proposed that prolactin is a risk factor for the development of
autoimmunity [1–4]. However, it remains unclear whether the
higher prolactin concentrations are the cause or consequence of
RA. There is increased risk of developing RA post-partum and this
further increases ﬁve-fold if breastfeeding [28–30] and disease
activity in RA improve with dopamine agonists [11–13]. This
suggests that prolactin may have a role in the pathogenesis, or at
least the modulation, of disease activity in RA. However, stress
increases serum prolactin concentration. It is therefore possible
that stress associated with RAmay be responsible for the increased
prolactin concentrations in RA, but this is unlikely because
cortisol, which also increases with stress, has been reported to be
similar or lower in subjects with RA than in controls [10, 20, 21].
In summary, we conﬁrm higher free prolactin concentrations in
subjects with RA. We have found no evidence to support the
notion that low biological activity macroprolactin contributes to
the elevated prolactin concentrations observed in RA.
The authors have declared no conﬂicts of interest.
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Pseudo-pseudohypercalcaemia, apparent primary
hyperparathyroidism and Waldenstro¨m’s macroglobulinaemia
A Elfatih, N R Anderson, M N Fahie-Wilson, R Gama
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An apparent primary hyperparathyroidism was reported due
to pseudo-pseudohypercalcaemia in a 74–year-old man with
Waldenstro¨m’s macroglobulinaemia. It is important to recog-
nise artificially elevated serum calcium levels so as to avoid
erroneous diagnosis, unnecessary investigations and poten-
tially inappropriate treatment.
W
aldenstro¨m’s macroglobulinaemia is a malignant
disorder of B lymphocytes characterised by high serum
concentrations of monoclonal IgM, a lymphoplasma-
cytic infiltrate of the bone marrow and an elevated serum
viscosity.1 2 Hypercalcaemia is unusual in Waldenstro¨m’s
macroglobulinaemia2 but a characteristic feature of primary
hyperparathyroidism. Although Waldenstro¨m’s macroglobuli-
naemia is uncommon, primary hyperparathyroidism is rela-
tively common. It is, therefore, possible that the two conditions
may coexist. We describe a case of apparent primary hyper-
parathyroidism due to pseudo-pseudohypercalcaemia in asso-
ciation with Waldenstro¨m’s macroglobulinaemia.
CASE REPORT
A 74-year-old man was diagnosed with Waldenstro¨m’s macro-
globulinaemia when he presented in May 2002 with lethargy,
weight loss and nasal bleeds, and an IgM k paraprotein of
31.5 g/l (IgM reference range: 0.5–2 g/l). He received chemo-
therapy courses and in February 2003 was referred to the
urologists with prostatism. His rectal examination was normal;
however, his serum prostate-specific antigen (PSA) was raised
(17 mg/l; reference range 0.1–6.5 mg/l; age >70 years). A four-
quadrant prostatic biopsy followed, but did not show malignant
infiltration of the prostate. At an oncology review in April 2003,
it was noticed that he had asymptomatic hypercalcaemia
(serum adjusted calcium level 2.86 mmol/l; reference range
2.17–2.66 mmol/l; Arsenazo III dye binding method). A
persistently elevated serum PSA of 52.2 mg/l measured in May
2003 had instigated a second four-quadrant prostatic biopsy,
which was inconclusive of a diagnosis of prostatic carcinoma.
Serum calcium levels remained elevated at 2.89 mmol/l. The
possibility of hypercalcaemia due to metastatic bone disease,
although uncommon in patients with prostate cancer despite
the high frequency of skeletal metastases, prompted an isotope
bone scan; however, it did not show any metastatic lesions. The
diagnosis of primary hyperparathyroidism was then considered
on the basis of the presence of a consistently elevated serum
adjusted calcium level of 3.03 mmol/l with inappropriately non-
suppressed two serum parathyroid hormone results (4 and
4.4 pmol/l; reference range 1.6–6.9 pmol/l, DPC immulite) and
a normal serum creatinine level of 94 mmol/l. Subsequently, an
ultrasound of the neck was performed, which suggested the
presence of a parathyroid adenoma in the posteroinferior part
of the left thyroid lobe. However, in July 2003, on metabolic
review, the presence of a normal serum ionised calcium level of
1.10 mmol/l (reference range 1.11–1.3 mmol/l measured on a
Radiometer ABL700) and a normal fasting urine calcium
excretion of 0.012 mmol/l GF (reference range CaE
,0.045 mmol/l GF) has excluded genuine hypercalcaemia
despite the repeatedly elevated serum adjusted calcium level
of 3.1 mmol/l.
The diagnosis of pseudohypercalcaemia was made and was
postulated to be due to an abnormal binding of calcium
molecules to the IgM paraprotein.3 This was, however, excluded
when gel filtration chromatography showed a similar pattern
between the patient’s sample and that of a normal control. Both
samples showed two peaks of calcium: the first peak associated
with albumin and the second peak represented the complexed
calcium; however, none was associated with the IgM para-
protein, thus excluding calcium–paraprotein binding as a cause
of the falsely elevated serum calcium levels. Additional
investigation with measurement of serum calcium level on
the same patient’s sample (serum adjusted calcium level of
3.1 mmol/l) with the o-cresolphthalein complexone (CPC)
method gave a calcium level of 2.19 mmol/l (reference range
2.1–2.55 mmol/l), and with atomic absorption spectrophoto-
metry gave a calcium level of 2.4 mmol/l (reference range 2.2–
2.6 mmol/l). All these findings led to the conclusion of
interference of the IgM paraprotein with the Arsenazo III dye
binding calcium method.4
In November 2003, histological examination of repeat four-
quadrant prostatic biopsies in the presence of a PSA of 79 mg/l
(reference range 0.1–6.5 mg/l; age >70 years) had confirmed
the diagnosis of an adenocarcinoma for which he is currently
receiving treatment.
Serum calcium level in January 2004, measured by a CPC
method, was 2.21 mmol/l (reference range 2.1–2.55 mmol/l).
Take-home messages
N It is important to investigate elevated serum calcium levels
in association with paraproteinaemias, especially in
patients with Waldenstro¨m’s macroglobulinaemia where
genuine hypercalcaemia is rare.
N True hypercalcaemia in these patients could be confirmed
by measurement of plasma ionised calcium with or
without urinary calcium excretion.
N Increased paraprotein concentrations in these patients
interfere with the calcium Arsenazo III reagent, and
elevated serum calcium level could be remeasured using
the o-cresolphthalein complexone method.
N Confirmation of falsely elevated serum calcium levels will
prevent erroneous diagnosis, unnecessary investigations
and potentially inappropriate treatment. Abbreviations: CPC, cresolphthalein complexone; PSA, prostate-specific
antigen
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DISCUSSION
The presence of pseudo-pseudohypercalcaemia in association
with Waldenstro¨m’s macroglobulinaemia had resulted in an
erroneous provisional diagnosis of primary hyperparathyroidism.
In patients with Waldenstro¨m’s macroglobulinaemia, genuine
hypercalcaemia is rare1 2 and pseudohypercalcaemia is even
rarer.3 4 Indeed, there were only two case reports of pseudohy-
percalcaemia in Waldenstro¨m’s macroglobulinaemia due to
either calcium binding to the IgM paraprotein3 or paraprotein
interference in the calcium Arsenazo III method.4 The findings for
this patient are consistent with the notion of IgM paraprotein
interference with the calcium Arsenazo III method and the
consequent pseudo-pseudohypercalcaemia.4 The mechanism of
the interference is likely to be increased turbidity produced by
paraprotein interaction with the acidic medium of the calcium
Arsenazo III reagent and not with the alkaline CPC method.4
It is possible that if the pseudo-pseudohypercalcaemia had not
been recognised, this patient would have had an unnecessary
neck exploration, since persistent hypercalcaemia (as in this case)
is an indication for parathyroid surgery irrespective of symptoms
or complications of primary hyperparathyroidism.5
CONCLUSION
We report a case of apparent primary hyperparathyroidism due
to pseudo-pseudohypercalcaemia in association with
Waldenstro¨m’s macroglobulinaemia.
We conclude that it is important to identify patients with
falsely elevated serum calcium levels in patients with para-
proteinaemias to prevent unnecessary investigations, erroneous
diagnosis and potentially inappropriate treatment.
Since pseudo-pseudohypercalcaemia in association with
Waldenstro¨m’s macroglobulinaemia may be multifactorial in
origin, we suggest that apparent hypercalcaemia in these
patients should be confirmed by measurement of plasma
ionised calcium with or without urinary calcium excretion.
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A distinctive vulval fibroma of so-called prepubertal type in a
postmenopausal patient
O O Ajibona, C J Richards, Q Davies
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The case of a 65-year-old female patient who has had a large
right vulval mass for over 30 years is reported here. The mass
was excised, but the hypocellular mesenchymal tumour was
difficult to classify histologically. On further specialist assessment,
it was found to be identical to the recently recognised distinctive
prepubertal vulval fibroma. These are very rarely reported in
children, and till now, has never been reported in an adult.
CASE REPORT
A 65-year-old postmenopausal woman was referred with a
painless vulval swelling that the patient had had for over
30 years. It had gradually increased in size over the past few
years, causing discomfort during sexual intercourse and when
riding a bicycle. It also caused an embarrassing bulge in her
leotard as she taught yoga. She remained fit and healthy. There
was no previous medical history of note. Examination revealed
a 9 cm65 cm65 cm soft, non-tender, non-reducible right
vulval mass with normal skin fully mobile over it. It was
partially fixed to underlying structures (fig 1).
MRI of the pelvis and perineum revealed a diffuse abnormality
causing enlargement of the right side of the vulva and perineum
extending from the infrapubic region to the anal margin. There
was extensive signal change within the perineal fat. No discrete
mass was seen and no lymphadenopathy was detected.
An initial incisional biopsy suggested that the unusual vulval
mass was a benign smooth muscle harmatoma without atypia or
malignancy. Surgical excision of the mass was performed with
excellent cosmetic results followed by further histological
assessment. This showed that the lesion was composed of bland
fibroblastic cells associated with abundant stromal collagen,
which seemed to be infiltrating and replacing large parts of the
submucosal tissue, entrapping nerves, vessels and adipose tissue
and extensively disrupting normal pre-existing smooth muscle
(fig 2). The cellularity was increased above the appearances,
normal at this site. The individual spindle cells had pale distinct
cytoplasm with bland nuclei and no conspicuous mitotic activity.
Immunostains showed CD34 positivity whereas S-100 protein
and smooth muscle actin were negative. The tumour stained
oestrogen and progesterone receptor negative. As the lesion was
difficult to classify, a specialist histological opinion was sought.
www.jclinpath.com
Standardization of glycated haemoglobin
I read the UKConsensus Statement Group’s letter1with
some concern over its apparent emphasis.
At present, clinical laboratories do not measure
HbA1c; they provide only a method-dependent indi-
cator of HbA1c content, harmonized by means of
correlation factors with a non-speci¢c (for HbA1c)
designated comparison method maintained by the
National Glycohaemoglobin Standardization Program
(NGSP) Core Laboratory.2 The numbers produced are
broadly comparable with the Diabetes Control and
Complications Trial (DCCT) and United Kingdom
Prospective Diabetes Study (UKPDS) evidence bases,
but they do not allow the science of HbA1c measure-
ment to advance. The International Federation of Clin-
ical Chemistry and Laboratory Medicine (IFCC)
reference measurement system for HbA1c (now de¢ned
in terms of a glycosylated hexapeptide)3 has the
potential to do this, which in turn, should improve
understanding and clinical e¡ectiveness of these
measurements.
In my view it is impossible to have your cake (`a
chemical speci¢c standardization anchor for HbA1c
measurement’) and eat it [ e`xpression of (HbA1c)
results (that) remain linked to DCCT/UKPDS values’].
A linear correlation between a properly calibrated,
speci¢c method for a single chemical entity and an un-
standardized non-speci¢c method for a mixture of
entities may be fortuitous and may not always be
applicable to individual patients’specimens.
Think of it by analogy, where a total haemoglobin
assay measures `all apples’, NGSP measures `all green
apples’ and IFCC measures `Granny Smiths’. If the
proportion of `Granny Smiths’ is considered to be the
marker of choice for a healthy apple cart, we should
measure that properly. An assay for `all green apples’
will always be an imperfect substitute although it may
have some value. During the development and appli-
cation of `Granny Smith’ assays, speci¢c assays for
other kinds of apple may be found to be more useful in
apple cart assessment in ways that are not yet
perceived.`Dumbing down’ new assay systems to make
them correlate with non-speci¢c assays, rather than
ensuring traceability to a speci¢c assay with method-
independent calibration, may inhibit exploitation of
their potential.
The apparent suggestion in the letter that the IFCC
system has to remain always linked to NGSP, seems
to perpetuate the myth that NGSP is somehow `right’
and the gold standard against which HbA1c reference
measurement systems should be compared. It is like
saying IDMS reference method values for cortisol
should be `anchored’ to the Matingley £uorimetric
method used before immunoassay became routine!
Once the IFCC system for HbA1c is established, it will
itself become the g`old standard’ against which HbA1c
values in all previous studies will have to be re-
assessed. Science must advance!
Clearly, the IFCC system must be evaluated and
prove itself, but its concept and design is scienti¢cally
superior to that of NGSP (and other standardization
systems), which it must replace as swiftly as practic-
able. This will enable an improved clinical knowledge
base to grow and £ourish rather than become `fossi-
lized’ with the DCCT/UKPDS data. All involved should
be promulgating this clear message, encouraging the
IFCC to complete its work, stimulating manufacturers
to embrace the new calibration and helping the
diabetes community come to terms with changes in
HbA1c values.
Jonathan Middle
UK NEQAS
PO Box 3909
Birmingham B15 2UE, UK
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Authors’ reply
We thank Dr Middle for his comments on our letter.
Like him, we recognize the inherent limitations of the
NGSPand have no wish to stand in the way of scienti¢c
advancement. However, the current system has
allowed a degree of harmony that has been immensely
useful in clinical diabetes management. It would
therefore seem imprudent to abandon this systemuntil
a more scienti¢cally rigorous and properly validated
replacement has been developed. At the time of writing
our original letter, there was no peer-reviewed
published information available on the relation of the
IFCC system to DCCT values and thus no evidence on
which to recommend a change.
The issue of changes in HbA1c values with a switch
in reference system is not simply one of di¡erent
numerical values or measuring di¡erent chemical
entities. The DCCT and UKPDS have for the ¢rst time
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allowed assessment of an individual’s risk of devel-
oping microvascular and macrovascular disease.Vali-
dation of any new system must include measures to
retain this relationship to HbA1c, which is essential to
delivering good diabetes care. This approach was
recently endorsed in a working group meeting of all
interested parties held under the auspices of the
European Association for the Study of Diabetes.
Like Dr Middle, we would strongly encourage the
proper development and evaluation of new standardi-
zation methods, with full peer review and open
discussion of all relevant issues.We are committed to
reviewing glycated haemoglobin standardization
programmes annually and a meeting is already
planned for June 2002.We very much hope there will
then be su¤cient data on the IFCC system in the public
domain to allow for planning of the way forward.
Sally M Marshall1
Philip D Home1
Garry John2
Susan E Manley3
1Department of Medicine
University of Newcastle Upon Tyne
2Department of Clinical Biochemistry
Norfolk and Norwich University Hospital
3Diabetes Research Laboratories
University of Oxford, UK
Audit of investigation of subclinical
hypothyroidism in Scottish laboratories
We agree with Dr Berry that development of standards
for interpretative comments for subclinical hypothyr-
oidism is desirable.1We suggest, however, some modi-
¢cations.
There was no attempt by the author to de¢ne either
subclinical or primary hypothyroidism. Most studies
de¢ne subclinical hypothyroidism as normal free
thyroxine (FT4) with thyroid stimulating hormone
(TSH) above the reference range, but distinguish
patients with a TSH above 10¢0mU/L, in whom thy-
roxine therapy is indicated.2^4 Case 2 has a TSH above
10¢0 mU/L, and we therefore suggest that it be
reported as c`onsistent with mild primary hypothy-
roidism, suggest repeat to con¢rm’.
We agree with Dr Berry that it is not, in general,
appropriate for the laboratory to recommend thy-
roxine therapy on the basis of laboratory results
alone,1but it can be useful if used cautiously.
While there was no case presented in the audit of a
patient with a raised TSH that was antibody-negative,
the standards should include this possibility. The
Whickham survey found that the annual risk of
developing hypothyroidism in women is 4¢3% per
annum if both a raised serum TSH and anti-thyroid
antibodies are present, and 2¢6% per annum if a raised
TSH alone is present. The algorithms developed by
bothWeetman3 and Ray et al.4 advocate repeat testing
in all patients with raised TSH, even if thyroid anti-
body-negative.
It is not necessary to delay measuring thyroid anti-
bodies. In most cases it is convenient to do this at the
same time and this knowledge will be useful to the
clinician for future patient management.
We propose the following scheme as a standard for
reporting results in ambulant patients, free from any
acute illness and not receiving thyroid-related
therapy:
1. If TSH above the reference range but below
10¢0 mU/L:
a. Estimation of thyroid antibodies.
b. Annual review, particularly in the presence of
positive thyroid antibodies which indicates the
increased risk of developing hypothyroidism in
such patients.
2. If TSH is410¢0mU/Lwhen associated with a low
normal FT4:
Results should be reported as c`onsistent with
mild primary hypothyroidism, suggest repeat to
con¢rm’. Thyroxine therapy should be recom-
mended cautiously, after excluding untreated
primary and secondary hypoadrenalism and
myocardial insu¤ciency.
3. Consider assay interference if the TSH is dispro-
portionately raised in comparison to the FT4 con-
centration and perform checks in the laboratory
before reporting.
4. In all acutely ill patients the comment should in-
clude repeat testing after recovery from the ill-
ness.
Annie Armston
Regional Endocrine Laboratory
Level D South Path Block
Southampton University NHS Trust
Southampton SO16 6YD, UK
Sudha Bulusu
Dept of Chemical Pathology
Newham General Hospital
London E13 8RU, UK
References
1 Berry P. Audit of investigation of subclinical hypothyroidism in
Scottish laboratories. Ann Clin Biochem 2001; 39: 26- 33
2 Vanderpump MPJ, Turnbridge WMG, French JM, Appleton D, Bates
D, Clark F, et al. The incidence of thyroid disorders in the community:
a twenty-year follow-up of the Whickham survey. Clin Endocrinol
1995; 43: 55- 68
Letters 535
Ann Clin Biochem 2002: 39: 534- 537
3 Weetman AP. Hypothyroidism: screening and subclinical disease.
BMJ 1997; 314: 1175- 8
4 Rae P, Farrar J, Beckett G, Toft A. Assessment of thyroid status in
elderly people. BMJ 1993; 307: 177- 80
Author’s reply
I thank DrArmston for her letter and suggested modi-
¢cations. It is recognized that the standards derived in
the paper are preliminary and will be modi¢ed with
time.
It is correct to say that most studies de¢ne subcli-
nical hypothyroidism as normal FT4 or total thyroxine
(TT4) and TSH above the reference range. This was the
de¢nition used in the study ^ it must have disap-
peared during a re-write. Case 2 falls within this de¢-
nition and we think that a repeat (as suggested by the
derived standard) is appropriate. There may be di¡er-
ences of opinion on exactly how long to wait before
repeating. Our repeat times are based on results from
an unpublished in-house audit which looked at
(among other things) long-term changes in TSH levels.
Our personal preference is to await the repeat results
before `labelling’ the patient.
We agree that it is sometimes justi¢able to recom-
mend thyroxine therapy or at least suggest it may be
appropriate if applied cautiously. We agree that all
patients with a normal FT4 and consistently raised
TSH who do not have raised TPO antibodies should
continue to have their thyroid function monitored.We
suggest this should be done at least annually
depending on theTSH level and clinical picture.
We agree that it may not be necessary to delay
measuring thyroid antibodies but there is a cost
penalty involved in performing this test on every
patient with a raised TSH and there may be logistical
problems for laboratories that send their samples to
reference laboratories.
Setting standards for an audit project such as this is
di¤cult. The derived standards must be applicable to
all patients with subclinical hypothyroid results and
must be acceptable to most people reporting thyroid
results. The suggested standards were considered to be
the minimum required. This means that the scheme
set out for commenting on patients with subclinical
hypothyroidism may appear somewhat simple. Many
laboratories will have much more sophisticated
reporting schemes. However, we believe the audit
project served its purpose and demonstrated the lack of
consistency of comments on subclinical hypothyroid
results both within and between laboratories.
With regard to the proposed scheme, clinical details
are rarely complete and it may not be possible to know
whether a patient is ambulant and free from acute (or
chronic) illness. We therefore believe a repeat is
advisable after a suitable time toallow the resolution of
any non-thyroid illness a¡ecting the results.
The cut-o¡ point of 10¢0 mU/L is widely used but is
suspiciously `round’.We believe that thyroid antibody
measurement can be useful in patients with a normal
FT4 (`low^normal’ would need de¢ning) and a TSH
above10¢0 mU/L.
We prefer to leave the decision to treat with thy-
roxine to the clinician who knows the patient.We may
occasionally mention that a patient with a consistently
raised TSH (even if it is below 10¢0mU/L) and raised
thyroid antibodies may bene¢t from a trial of thyroxine
but this is usually done because general practitioners
are relatively unfamiliar with the signi¢cance of raised
thyroid antibodies.We do not do it routinely and do not
feel it should be a reporting standard.
We agree with Dr Armston regarding acutely ill
patients and with her comments for assay interference
but would suggest that the checks include assaying the
sample by a di¡erent method.
P Berry
Biochemistry Department
Monklands Hospital
Lanarkshire ML6 0JS, UK
Limited clinical utility of high-sensitivity
plasma C-reactive protein assays
We wish to make a further observation about the
limited clinical utility of single hs-C-reactive protein
(CRP) measurement in coronary heart disease (CHD)
risk assessment.1 It has been suggested that CRP
values can be incorporated into CHD risk assessment
to improve prediction of CHD morbidity.2 Assessment
of CHD risk usually involves opportunistic screening
in primary care.3 We measured hs-CRP by immu-
noassay (DPC, Los Angeles CA, USA) in 434 subjects
from primary care in whom a laboratory-based CHD
risk score calculation had been requested. Of these,113
(26¢0%) subjects had hs-CRP concentrations above
6¢0mg/L (detection limit of ordinary CRP assays) and
32 subjects (7¢3%) had CRP values 415 mg/L,
suggesting an active in£ammatory process probably
due to a minor illness. These results suggest that using
CRP during opportunistic screening may falsely
increase CHD risk score, leading to inappropriate
patient management.
Furthermore, in£ammatory processes, indicated by
elevated CRP, may be associated with lowering of total
cholesterol and high density cholesterol concentra-
tions,4 which may in turn in£uence calculated CHD
risk scores. Our results have shown that a signi¢cant
number of patients who have undertaken opportu-
nistic screening may have minor or subclinical illness
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that could a¡ect their CHD risk scores and adversely
in£uence their management.
Health care practitioners should be aware of the
potential limitations of the use of CRP and opportu-
nistic screening in CHD risk assessment.
A Elfatih
K Chatha
NR Anderson
R Gama
Department of Clinical Chemistry
New Cross Hospital
Wolverhampton WV10 0QP, UK
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`Glucose meter hypoglycaemia’: often a non-disease
R Gama1, N R Anderson1 and V Marks2
From the 1Department of Clinical Chemistry, New Cross Hospital, Wolverhampton, West Midlands
WV10 0QP and the 2European Institute of Health and Medical Sciences, University of Surrey,
Guildford, Surrey, UK
The diagnosis of hypoglycaemia depends upon
the demonstration of a low blood glucose
concentration during a spontaneous sympto-
matic episode. Glucose monitoring devices may
misdiagnosemany healthy individuals with non-
speci®c symptoms as having hypoglycaemia.We
present three illustrative cases of `glucose meter
non-hypoglycaemia’.
CASE 1
A 31-year-old housewife gave a 20-year history
of intermittent fatigue and `shakes’ unrelated to
food or exercise. She attributed these symptoms
to hypoglycaemia when a nurse recognized the
`symptoms of hypoglycaemia’ and checked her
capillary blood glucose on a meter, which gave a
low reading (1´9mmol/L) (uncon®rmed however
by laboratory measurement) during inpatient
investigations for abdominal pain 1 year pre-
viously. Her GP then provided her with blood
glucose reagent strips. She visually recorded her
glucose being as low as 1±2mmol/L when
symptomatic, and was therefore referred for
assessment.
During an exercise test following an 18-h fast
her plasma venous glucose rose from 4´3 to
4´7mmol/L and her insulin concentrations were
low, at 525 pmol/L. During a prolonged (5-h)
75g glucose load test her nadir plasma venous
glucose was 5´5mmol/L at 240min, but she
experienced `shakes and tiredness’ when her
plasma venous glucose was 6´9mmol/L at
180min.
We explained that hypoglycaemia was un-
likely to explain her symptoms. We suggested
that she should have a blood sample collected
when symptomatic and taught her how to collect
capillary blood into a ¯uoride capillary tube.
She was unhappy with our explanation and
never reattended.
CASE 2
A 29-year-old female nurse gave a 3-year history
of intermittent disorientation, sweats and
lethargy unrelated to food or exercise. While at
work, during two of these attacks ®nger-prick
blood samples gave low glucose meter readings
(52´0mmol/L). She was referred for further
assessment. An exercise test following an 18-h
fast and a 5-h 75 g glucose load test, during
which she was asymptomatic, provided no
evidence for hypoglycaemia.
During one of her symptomatic episodes a
glucose meter reading was 1´1mmol/L, but
simultaneously collected laboratory capillary
blood glucose was 5´5mmol/L. She accepted
that her symptoms were not due to hypoglycae-
mia and that her previous readings were due
either to faulty technique or to a faulty meter.
CASE 3
While at work during a period of personal stress,
a 24-year-old female nurse felt dizzy with sweats,
nausea and `shakes’. A nursing colleague using a
glucose meter found her to have a reading of
1´6mmol/L. She was therefore given oral
glucose, which led to a resolution of the
symptoms after 30min. During a further similar
attack 3 months later she was seen in an
Accident and Emergency department with a
label of hypoglycaemia and her glucose meter
reading was con®rmed as `low’. She was given
oral glucose and discharged with recommenda-
tions that she be investigated further. An
exercise test following an 18-h fast and a 5-h
75 g glucose load test, during which she was
asymptomatic, provided no evidence for hypo-
glycaemia. We explained that her symptoms
were unlikely to be due to hypoglycaemia. As
her personal stress resolved she had no further
symptomatic episodes.
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DISCUSSION
Glucose meters have been justi®ably popular for
over 15 years and have advanced the manage-
ment of diabetic patients. However, glucose
meters, and especially visually read glucose test
strips, are unsuitable for the diagnosis of
spontaneous hypoglycaemia in the domestic
environment, as many of the methods used
may be unreliable in the hypoglycaemic range.1±5
Faulty meters, faulty blood strips, faulty patient
preparation and faulty analytical technique may
also add to the considerable risk of erroneous
results.3 Glucose meters may however be useful
in the clinical environment (e.g. in Accident and
Emergency departments) as a rapid guide to the
need for further blood collection (for con®rma-
tion and further investigation), followed imme-
diately by the administration of glucose to
relieve symptoms.
In the cases described here the subjects were
initially `investigated’ in three different hospi-
tals, suggesting that `hypoglycaemia’ was diag-
nosed using different types of meter. This
suggests that any errors were probably due to
faulty technique, but does not exclude instru-
ment or reagent error. It also implies that the use
of glucose meters to investigate vague symptoms
for hypoglycaemia may be widespread.
It is likely that the simplicity and ready
availability of glucose meters has led to their
inappropriate use in the investigation of non-
speci®c symptoms for the possibility of hypogly-
caemia. The majority of `patients’ seen in our
departments with `glucose meter non-hypogly-
caemia’ have been mislabelled as having hypo-
glycaemia within the hospital environment
without laboratory con®rmation, even though
suppliers of glucose meters generally recommend
that meter readings52´0mmol/L be veri®ed by
a laboratory glucose measurement. It is particu-
larly important to obtain a laboratory glucose
measurement, ®rstly to con®rm or refute
hypoglycaemia, and secondly, if hypoglycaemia
is con®rmed, as the ideal (and sometimes the
only) opportunity to uncover its underlying
aetiology. Also of concern, but dif®cult to
identify, is that the indiscriminate use of glucose
meters may misclassify subjects with genuine
spontaneous hypoglycaemia as being normogly-
caemic.
An important adverse consequence of mis-
labelling healthy people with a disease is a
reduction in their quality of life, and in some
individuals the adoption of a sick role (`the
worried well’). The mislabel of `hypoglycaemia’
in these patients can however often be dif®cult to
rectify, perhaps because patients who present
with symptoms of hypoglycaemia may have
abnormal psychological pro®les.6 Although a
prolonged glucose load test is of limited value in
the investigation of hypoglycaemia,5±8 the occur-
rence of symptoms in the absence of biochemical
hypoglycaemia may help convince patients that
their symptoms are not due to hypoglycaemia.
The misdiagnosis of hypoglycaemia may also
result in unnecessary and wasteful investiga-
tions, and may in part explain why 57% of
samples received in a supraregional laboratory
for the investigation of hypoglycaemia were
inappropriate, having glucose values of greater
than 3´0mmol/L.9
In summary, we suggest that the use of
glucose meters to diagnose spontaneous hypo-
glycaemia (without laboratory con®rmation) is
inappropriate, wasteful of resources and may
adversely affect the health of the individual.
Patients with symptoms suggestive of neuro-
glycopenia should be appropriately assessed and
investigated.9 We recommend that training of
personnel in the use of glucose meters should
include the inappropriateness of their routine
use in investigating spontaneous hypoglycaemia
in non-diabetic adults.
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